        <DOC>
            	<DOCNO>s_2092_0_0</DOCNO>
            	<TEXT>By holding a great stock over the long term the potential gain will vastly surpass what you may gain from moving some of the investment to what is traditionally referred to as a safer investment.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_0_1</DOCNO>
            	<TEXT>It all depends on a number of items.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_0_2</DOCNO>
            	<TEXT>Will you be needing some of the money in the short term?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_0_3</DOCNO>
            	<TEXT>Can you sleep at night with the fluctuations in the stock price?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_0_4</DOCNO>
            	<TEXT>Have you done your DD and have confidence in your investment?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_0_5</DOCNO>
            	<TEXT>Do you have the ability to wait for the stock to realize it's potential?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_0_6</DOCNO>
            	<TEXT>I have done my DD on SRNE and know, not think, that the future is bright and am willing to ride the turbulence of the stock price and willing to wait for 1 to 2 years or more for the company to reach it's full potential.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_0_7</DOCNO>
            	<TEXT>I f you want short term gains other established growth companies may be a better fit for some of your funds..... I also do not buy or sell options.........</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_1_0</DOCNO>
            	<TEXT>Very possibly another successful program in which Sorrento is involved in...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_2_0</DOCNO>
            	<TEXT>Interesting thought.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_2_1</DOCNO>
            	<TEXT>Any guesses on who that might be if it does take place?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_3_0</DOCNO>
            	<TEXT>Very interesting..</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_4_0</DOCNO>
            	<TEXT>Without any doubt on my part the pps has bee manipulated for the benefit of whomever!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_4_1</DOCNO>
            	<TEXT>I agree it it due time for that earth shattering news release to bring it to an end.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_4_2</DOCNO>
            	<TEXT>I have been adding to my position on every drop in price and will continue to do so!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_5_0</DOCNO>
            	<TEXT>I agree, over the next year or 2 we will be THE desired Biotherapeutic to own and now is the time to load up and wait.....</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_6_0</DOCNO>
            	<TEXT>Welcome Rocket-890!!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_7_0</DOCNO>
            	<TEXT>Certainly need an update on the progress of the purchase of ANP.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_7_1</DOCNO>
            	<TEXT>I had contacted IR earlier today without a response.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_7_2</DOCNO>
            	<TEXT>Hopefully you can get some answers..... I do understand that the acquisition was through a subsidiary of Sorrento and it's possible the terms are still in negotiation......</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_8_0</DOCNO>
            	<TEXT>Nice find for a Tuesday am!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_8_1</DOCNO>
            	<TEXT>This week could be the turning point we have been waiting for..</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_9_0</DOCNO>
            	<TEXT> Sorrento keeps advancing the progress of it's programs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_9_1</DOCNO>
            	<TEXT>It's only a matter of time until the floodgates open, the shorts get washed away and the pps rises significantly, never to visit single digits again.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_9_2</DOCNO>
            	<TEXT>No one knows when this will take place, this is why you must hold your position through the volatility and add when a sale is presented and gifted to you...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_10_0</DOCNO>
            	<TEXT>Totally agree.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_10_1</DOCNO>
            	<TEXT>Dr Ji was very impressive in his presentation and also in the group discussion!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_10_2</DOCNO>
            	<TEXT>a grand slam day..</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_11_0</DOCNO>
            	<TEXT>Great re-cap, thanks...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_12_0</DOCNO>
            	<TEXT>Sorry to hear of your ( our loss) tonight.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_12_1</DOCNO>
            	<TEXT>Being, a Veteran, I have a 25 Foot flag pole in my front yard, It will be raised in the morning and then lowered to half staff in his honor.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_12_2</DOCNO>
            	<TEXT>At my age I have lost many of my army buddies over the years and feel your loss my friend........</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_13_0</DOCNO>
            	<TEXT>There is no way we stay flat for the next 12 months.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_13_1</DOCNO>
            	<TEXT>Overdue for positive results and news of such.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_13_2</DOCNO>
            	<TEXT>I expect double digit pps by the end of year, maybe much sooner...so many irons in the fire...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_14_0</DOCNO>
            	<TEXT>Growing pains is what is expected with small bios, especially those which are so promising with a great pipeline and being shorted to the extent Sorrento is.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_14_1</DOCNO>
            	<TEXT>Shorts have been covering as they know they're playing with a lit stick of dynamite.. One of these days they will all be rushing for the exit and most will be caught in the explosion of a squeeze....</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_15_0</DOCNO>
            	<TEXT>The CEO had a great presentation which was precise and inspiring...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_16_0</DOCNO>
            	<TEXT>I agree, I check out the SRNE yahoo board very seldom anymore.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_16_1</DOCNO>
            	<TEXT>The bashers, shorts, morons and multiple ID idiots have ruined it for me and many other.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_16_2</DOCNO>
            	<TEXT>This is why I'm here where those undesirables can be eliminated from our community.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_16_3</DOCNO>
            	<TEXT>Enjoy, participate and encourage others to join us...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_17_0</DOCNO>
            	<TEXT>A true long should not be upset or disappointed in seeing the pps drop as it has this past week.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_17_1</DOCNO>
            	<TEXT>A true long is just that, a long term investor and should look to this past week as an opportunity to ad to his/her position.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_17_2</DOCNO>
            	<TEXT>This most likely will not be the last time the shorts and manipulators hammer the stock price, free up some funds in anticipation of this type of opportunity...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_18_0</DOCNO>
            	<TEXT>Sometimes we see more in a news release than what is really there or at least we hope there is more there and therefore look for hidden meanings into what we have read.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_18_1</DOCNO>
            	<TEXT>We all hope for positive results and news of such quickly, even though the progress is slow and will take time.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_18_2</DOCNO>
            	<TEXT>News releases are merely reinforcement of what is to come as we wait for the eventual outcome, which I believe will reward those who do wait, handsomely!!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_0</DOCNO>
            	<TEXT>Don's Post from yahoo</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_1</DOCNO>
            	<TEXT>Don's post from yahoo: STIX / ABIVERTINIB / SP102 / DROPSAll have near term news.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_2</DOCNO>
            	<TEXT>All have billion dollar markets.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_3</DOCNO>
            	<TEXT>The other 72+ Sorrento programs can be financed by the profits from these 4 programs alone.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_4</DOCNO>
            	<TEXT>I was glad to see the new updated corporate presentation. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_5</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/static-files/da3ae428-94af-47fc-b20f-5cab2e10b54e](https://investors.sorrentotherapeutics.com/static-files/da3ae428-94af-47fc-b20f-5cab2e10b54e).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_6</DOCNO>
            	<TEXT>\*\*\*PHASE 3, close to EUA or close to market (13 programs) 1.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_7</DOCNO>
            	<TEXT>Abivertinib NSCLC NDA filed China 2.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_8</DOCNO>
            	<TEXT>Abivertinib NSCLC ph.3 completed US 3.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_9</DOCNO>
            	<TEXT>PD-L1 SCLC partnered 4.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_10</DOCNO>
            	<TEXT>Erbitux biosimilar 5.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_11</DOCNO>
            	<TEXT>Xolair biosimilar 6.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_12</DOCNO>
            	<TEXT>Remicade biosimilar(approved in China.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_13</DOCNO>
            	<TEXT>SRNE holds ROW rights!)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_14</DOCNO>
            	<TEXT>SP-102 sciatica 8.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_15</DOCNO>
            	<TEXT>RTX Osteo Arthritis 9.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_16</DOCNO>
            	<TEXT>RTX cancer pain 10.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_17</DOCNO>
            	<TEXT>Covi-Stix EUA application(approval in Mexico...25million shipped!)DOD CRADA 11.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_18</DOCNO>
            	<TEXT>Covi-Trace EUA application 12.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_19</DOCNO>
            	<TEXT>Sofusa Enbrel 13.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_20</DOCNO>
            	<TEXT>Cynviloq (part of PSS lawsuit)\*\*\*PHASE 2 (13 programs) 14.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_21</DOCNO>
            	<TEXT>Seprehvir Oncolytic virus 15.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_22</DOCNO>
            	<TEXT>Covi-MSC EUA potential 16.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_23</DOCNO>
            	<TEXT>Covi-AMG EUA potential DOD CRADA 17.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_24</DOCNO>
            	<TEXT>COVIDROPS EUA potential DOD CRADA 18.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_25</DOCNO>
            	<TEXT>Covi-Track EUA pre-validation DOD CRADA 19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_26</DOCNO>
            	<TEXT>PD-L1 partnered 20.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_27</DOCNO>
            	<TEXT>Herceptin delivery partnered 21.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_28</DOCNO>
            	<TEXT>Abivertinib Lymphoma 22.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_29</DOCNO>
            	<TEXT>Abivertinib Covid 19 EUA potential as soon as August 23.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_30</DOCNO>
            	<TEXT>Abivertinib prostate cancer ph.2 IND 24.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_31</DOCNO>
            	<TEXT>Abivertinib Lupus ph.2 IND 25.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_32</DOCNO>
            	<TEXT>Abivertinib hairy cell leukemia 26.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_33</DOCNO>
            	<TEXT>CD47 partnered\*\*\*PHASE 1, IND filed or pre-IND (46+ programs) 27.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_34</DOCNO>
            	<TEXT>Seprehvec Oncolytic Virus 28.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_35</DOCNO>
            	<TEXT>CD 38 CAR-T ph.1 29.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_36</DOCNO>
            	<TEXT>CEA CAR-T ph.1 30.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_37</DOCNO>
            	<TEXT>CD38 DAR-T ph.1 31.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_38</DOCNO>
            	<TEXT>BCMA DAR-T pre-IND 32.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_39</DOCNO>
            	<TEXT>PD-L1(C/DAR-T) pre-IND 33.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_40</DOCNO>
            	<TEXT>CyCART-19 partnered 34.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_41</DOCNO>
            	<TEXT>Covi-GeneMab pre-IND $34 million DARPA funding 35.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_42</DOCNO>
            	<TEXT>PD1-GeneMab pre-IND 36.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_43</DOCNO>
            	<TEXT>ERT (Enzyme Replacement Therapy) several pre IND programs 37.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_44</DOCNO>
            	<TEXT>IL2Teff pre-IND 38.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_45</DOCNO>
            	<TEXT>IL2Treg pre-IND 39.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_46</DOCNO>
            	<TEXT>Sofusa anti-PD1 and anti-CTLA4 40.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_47</DOCNO>
            	<TEXT>TNF-a (Enbrel) ph.1 41.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_48</DOCNO>
            	<TEXT>CTLA-4 (Yervoy) 42.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_49</DOCNO>
            	<TEXT>CD47 ph.1 basket trial partnered 43.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_50</DOCNO>
            	<TEXT>TROP2 IND granted in China...partnered.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_51</DOCNO>
            	<TEXT>BCMA ADC pre-IND 45.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_52</DOCNO>
            	<TEXT>ROR1 ADC pre-IND 46.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_53</DOCNO>
            	<TEXT>CD25 ADNAB pre-IND 47.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_54</DOCNO>
            	<TEXT>CD20 ADNAB (Rituxan) IIT-ph.1 48.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_55</DOCNO>
            	<TEXT>VEGF(Avastin) ADNAB IIT-ph.1 49.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_56</DOCNO>
            	<TEXT>PD-L1 ADNAB pre-IND 50.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_57</DOCNO>
            	<TEXT>VEGFR2 ADNAB pre-IND 51.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_58</DOCNO>
            	<TEXT>CBD immune diseases pre-IND 52.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_59</DOCNO>
            	<TEXT>CBD insomnia pre-IND 53.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_60</DOCNO>
            	<TEXT>CBD Parkinsons pre-IND 54.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_61</DOCNO>
            	<TEXT>CBD CNS diseases pre-IND 55.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_62</DOCNO>
            	<TEXT>PD-L1 CAR-NK partnered 56.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_63</DOCNO>
            	<TEXT>CD38 CAR-NK to be partnered 57.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_64</DOCNO>
            	<TEXT>CD38 ADC AL Amyloidosis 58.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_65</DOCNO>
            	<TEXT>AC0058 ph.1b lupus 59.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_66</DOCNO>
            	<TEXT>AC0058 pre-IND MS 60.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_67</DOCNO>
            	<TEXT>AC0939 pre-IND CNS indications 61.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_68</DOCNO>
            	<TEXT>A166 HER2 ADC phase 1 62.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_69</DOCNO>
            	<TEXT>Karolinska off-the-shelf DAR-NK pre-IND 63.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_70</DOCNO>
            	<TEXT>Covid mRNA vaccine(Sofusa delivery)38.low cost C1 based multivalent vaccine(rights to 60% of world population) 64.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_71</DOCNO>
            	<TEXT>Salicyn-30 oral antiviral40.MP18 oral antiviral MPro inhibitor41.Combination oral antiviral drug cocktail42.RESPISTIX Combination Covid/seasonal flu tests43.Combination Covid/seasonal flu vaccine44 advanced Animal Health subsidiary 65.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_72</DOCNO>
            	<TEXT>1,000,000+ small molecule library 66.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_73</DOCNO>
            	<TEXT>Twenty quadrillion antibody library FUNDING?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_74</DOCNO>
            	<TEXT>Sorrento has invested wisely and has millions of shares of ImmunityBio, Celularity and ImmuneOncia.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_75</DOCNO>
            	<TEXT>These are worth many hundreds of millions and the PSS binding arbitration will be settled with very large potential gains.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_76</DOCNO>
            	<TEXT>It has many attractive programs to partner for upfront, milestone and royalty payments!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_77</DOCNO>
            	<TEXT>The first of many EUA's will produce revenues within weeks(Mexico)as 25 million testkits are being shipped.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_78</DOCNO>
            	<TEXT>And SP-102 sales will begin in 2022 with multi-billion potential.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_79</DOCNO>
            	<TEXT>Huge portfolio AND huge assets!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_19_80</DOCNO>
            	<TEXT>Sorrento is in the early days of becoming(or being acquired by...) a Big Pharma!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_20_0</DOCNO>
            	<TEXT>EUA for ACON Labs</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_20_1</DOCNO>
            	<TEXT># [Coronavirus (COVID-19) Update: FDA Authorizes Additional OTC Home Test to Increase Access to Rapid Testing for Consumers](https://lnks.gd/l/eyJhbGciOiJIUzI1NiJ9.eyJidWxsZXRpbl9saW5rX2lkIjoxMDEsInVyaSI6ImJwMjpjbGljayIsImJ1bGxldGluX2lkIjoiMjAyMTEwMDQuNDY4Nzc0NzEiLCJ1cmwiOiJodHRwczovL3d3dy5mZGEuZ292L25ld3MtZXZlbnRzL3ByZXNzLWFubm91bmNlbWVudHMvY29yb25hdmlydXMtY292aWQtMTktdXBkYXRlLWZkYS1hdXRob3JpemVzLWFkZGl0aW9uYWwtb3RjLWhvbWUtdGVzdC1pbmNyZWFzZS1hY2Nlc3MtcmFwaWQtdGVzdGluZz91dG1fbWVkaXVtPWVtYWlsJnV0bV9zb3VyY2U9Z292ZGVsaXZlcnkifQ.n_1J5k1wblFmD5QpjasZOm5P0VryzfhMDHf2ax3hyMs/s/1419462572/br/113348250578-l) ### The following is attributed to Jeff Shuren, M.D., J.D., director of FDAs Center for Devices and Radiological Health Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the ACON Laboratories Flow*flex* COVID-19 Home Test, an over-the-counter (OTC) COVID-19 antigen test, which adds to the growing list of tests that can be used at home without a prescription.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_20_2</DOCNO>
            	<TEXT>This action highlights our continued commitment to increasing the availability of appropriately accurate and reliable OTC tests to meet public health needs and increase access to testing for consumers.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_20_3</DOCNO>
            	<TEXT>Todays authorization for the ACON Laboratories Flow*flex* COVID-19 Home Test should significantly increase the availability of rapid, at-home tests and is expected to double rapid at-home testing capacity in the U.S. over the next several weeks.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_20_4</DOCNO>
            	<TEXT>By years end, the manufacturer plans to produce more than 100 million tests per month, and this number will rise to 200 million per month by February 2022.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_21_0</DOCNO>
            	<TEXT>No mention in the announcement of the effectiveness of the test kit, but a warning of possible false readings.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_21_1</DOCNO>
            	<TEXT>Hey FDA, look at COVI-STIX please....</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_22_0</DOCNO>
            	<TEXT>Rest in Peace Chick......  Robert, is that 11:30 Eastern time?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_22_1</DOCNO>
            	<TEXT>I want to pause from whatever I'm doing at that time..</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_23_0</DOCNO>
            	<TEXT>Over 90 test kits under review.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_23_1</DOCNO>
            	<TEXT>It will depend on the effectiveness and sensitivity of each to receive approval.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_24_0</DOCNO>
            	<TEXT>Opportunities are world wide from Asia, Europe, South America and North America excluding the USA it seems... Wake up FDA!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_25_0</DOCNO>
            	<TEXT>There is no way to know when the hammer falls, that is why the 'shorts' are so nervous posting constantly over on the yahoo board.. Even they know it's coming, only a matter of when and how hard!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_26_0</DOCNO>
            	<TEXT>May 13th we were at 6.35 and then news came out and within 6 weeks we hit 11.00.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_26_1</DOCNO>
            	<TEXT>This shows me that with and EUA or other solid news we once again will surge into double digits, not to return to single digits as the 'shorts' will decide it's time to move on...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_27_0</DOCNO>
            	<TEXT>Saturday means football!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_27_1</DOCNO>
            	<TEXT>Good morning all!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_27_2</DOCNO>
            	<TEXT>Today's games I want to catch are; Tx-Okla, Ark-Miss, Penn st-Iowa; Lsu-Ky. There are many other great games such as Mich-Neb.......</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_28_0</DOCNO>
            	<TEXT>Maybe KY finally has a winning team, it's been many years since they were a contender in the toughest conference.... My Tenn hasn't had a contender since Manning!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_29_0</DOCNO>
            	<TEXT>Ark will hogtie Miss... and Tx will hook the sooner wagon for a win!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_29_1</DOCNO>
            	<TEXT>All others I agree.. I might add, KY will beat LSU!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_30_0</DOCNO>
            	<TEXT> tenn 35 SC 0, and not even half time!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_30_1</DOCNO>
            	<TEXT>RIP Gamecocks!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_30_2</DOCNO>
            	<TEXT>OKLA having a tough time with the TX defense, one of the best in the country...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_31_0</DOCNO>
            	<TEXT>From Seeking Alpha this morning.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_31_1</DOCNO>
            	<TEXT># Sorrento Therapeutics: Wide Oncology Pipeline, And Watch Out For COVID Updates Oct. 09, 2021 6:38 AM ET[**Sorrento Therapeutics, Inc. (SRNE)**](https://seekingalpha.com/symbol/SRNE?source=content_type%3Areact%7Csection%3Amain_content%7Csection_asset%3Ameta%7Cfirst_level_url%3Aarticle%7Csymbol%3ASRNE)[5 Comments](https://seekingalpha.com/article/4459163-sorrento-therapeutics-wide-oncology-pipeline-and-watch-out-for-covid-updates#comments)6 Likes ## Summary * First, a striking point about Sorrento Therapeutics is that despite its $1.93 billion market cap, it possesses a wide pipeline, similar to the biggest biopharmaceuticals. *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_31_2</DOCNO>
            	<TEXT>Second, it is also generating revenues mainly from a prescription drug and has been able to get EUA approval for COVISTIX testing kits, a space that should be closely watched by investors before investing. *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_31_3</DOCNO>
            	<TEXT>On the other hand, it is spending colossal amounts on clinical development, has debts with limited cash at hand. *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_31_4</DOCNO>
            	<TEXT>Not possessing any first-mover advantage, its anti-COVID therapies still matter given the prevalence of highly infectious variants and the time-limited protection conferred by vaccines. *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_31_5</DOCNO>
            	<TEXT>Analyzing the pipeline, there are assets which the company could monetize in the worst-case scenario that finances cannot be raised to fund promising oncology operations or service debt.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_32_0</DOCNO>
            	<TEXT>Both top 2nd tier teams.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_32_1</DOCNO>
            	<TEXT>both would be contenders in any other conference...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_33_0</DOCNO>
            	<TEXT>Click the link to read the entire article from Seeking Alpha..</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_34_0</DOCNO>
            	<TEXT>I do well with both College Football and Basketball, about 65%.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_34_1</DOCNO>
            	<TEXT>I use "BETONLINE" to place 2 team parlays.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_34_2</DOCNO>
            	<TEXT>6 to 8 bets per week and win 65%.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_34_3</DOCNO>
            	<TEXT>Each bet pays approx 2.5X the bet.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_34_4</DOCNO>
            	<TEXT>Making money while waiting for Sorrento to cross the goal line!!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_35_0</DOCNO>
            	<TEXT>7 to 10, close game of from 2 good teams.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_35_1</DOCNO>
            	<TEXT>If they can pull a win vs Iowa then Penn st at Ohio st on the 30th should show who is tops in the B10!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_36_0</DOCNO>
            	<TEXT>No reason to make that toss up pass.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_37_0</DOCNO>
            	<TEXT>Michigan hasn't played a tough 1st half of their schedule.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_37_1</DOCNO>
            	<TEXT>The 2nd half will show who they are...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_38_0</DOCNO>
            	<TEXT>Gotta be a great memory...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_39_0</DOCNO>
            	<TEXT>Great close game!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_39_1</DOCNO>
            	<TEXT>LSU - KY should also be...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_40_0</DOCNO>
            	<TEXT>Iowa has an easy remaining schedule, not playing Mich, Ohio St or Mich St...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_41_0</DOCNO>
            	<TEXT>Mexico, and hopefully very soon in Brazil and Canada...and then throughout the world to follow....</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_42_0</DOCNO>
            	<TEXT>The US FDA is financed by big pharma and will not give Covi-stix a 2nd look until they see approvals elsewhere and they feel they have no choice to save face.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_42_1</DOCNO>
            	<TEXT>The system needs to be changed where funding for the FDA does not come from special interests with their own agenda to keep out small bios with better product!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_43_0</DOCNO>
            	<TEXT>I don't place many bets on pro football, but I did bet a parlay taking Pitts and Cinci with the points.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_44_0</DOCNO>
            	<TEXT>The Sunday night game, Buff at KC should be a good one.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_44_1</DOCNO>
            	<TEXT>growing up in Western NY the Bills were my team.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_44_2</DOCNO>
            	<TEXT>They began in 1960 when I was 12.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_45_0</DOCNO>
            	<TEXT>NCAA Rankings</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_45_1</DOCNO>
            	<TEXT>Let's have some fun predicting the rankings coming out in the morning.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_45_2</DOCNO>
            	<TEXT>Mine are; 1.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_45_3</DOCNO>
            	<TEXT>Mich Well, do you agree or do you think Alabama will only drop to 2nd or 3rd?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_46_0</DOCNO>
            	<TEXT>It has nothing to do with SRNE.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_46_1</DOCNO>
            	<TEXT>It is only a way to unwind and relax on this Sunday.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_46_2</DOCNO>
            	<TEXT>Looking over your comments, which are all negative, you more than anyone need to relax.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_46_3</DOCNO>
            	<TEXT>I know it's frustrating to watch the pps drop week after week, but waiting is all we can do as we have no control over the processes involved.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_46_4</DOCNO>
            	<TEXT>You have 27K shares, I have close to that number and am willing to wait it out.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_46_5</DOCNO>
            	<TEXT>Selling and moving on is the only other option, one in which I believe would be a big mistake... Have good and relaxing evening...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_47_0</DOCNO>
            	<TEXT>Absolutely, If someone wants to talk about his favorite BBQ recipe or his favorite movie or anything else, do so.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_47_1</DOCNO>
            	<TEXT>No one has to participate if he chooses not to.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_47_2</DOCNO>
            	<TEXT>If it helps while we wait for the inevitable, but yes, frustrating, end result of investing in Sorrento, then so be it.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_47_3</DOCNO>
            	<TEXT>If you have done your DD then you know what you own!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_48_0</DOCNO>
            	<TEXT>Without doubt there is more in the works.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_48_1</DOCNO>
            	<TEXT>I will agree that SP-102 is the logical reason for the new hires and not strictly ZTlido.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_48_2</DOCNO>
            	<TEXT>I have very much pain in both shoulders due to arthritis and tried to get ZTlido but the VA won't offer it due to the cost factor.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_48_3</DOCNO>
            	<TEXT>They send my a patch that is 6% Lidocaine and doesn't do much good, better than what is available OTC though..</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_49_0</DOCNO>
            	<TEXT>Momentous preparation for tremendous growth to this extent is what all investors should hope for in the companies they chosen to invest in.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_49_1</DOCNO>
            	<TEXT>Adding on every opportunity!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_50_0</DOCNO>
            	<TEXT>Voted this morning...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_51_0</DOCNO>
            	<TEXT>Great review and reminder of the progress of Abivertinib.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_51_1</DOCNO>
            	<TEXT>Yes, we are overdue for a news release of pipeline progress or partnership update..</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_52_0</DOCNO>
            	<TEXT>News release Today!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_52_1</DOCNO>
            	<TEXT># News Release # FDA Authorizes Sorrento Phase 2 Trial of Epidural Resiniferatoxin for the Orphan Indication of Control of Intractable Cancer Pain October 13, 2021 at 9:00 AM EDT[Download PDF](https://investors.sorrentotherapeutics.com/node/12731/pdf) * Phase 2 trial of resiniferatoxin (RTX) to proceed following clearance from FDA. *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_52_2</DOCNO>
            	<TEXT>The decision is supported by the Phase 1 data confirming RTX safety for epidural administration without dose limiting toxicity at any doses tested up to 30 ug. *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_52_3</DOCNO>
            	<TEXT>Safety and initial pain relief observed in patients with advanced cancer support RTX as a good candidate for long-term control of refractory cancer pain in a broad spectrum of patients. *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_52_4</DOCNO>
            	<TEXT>RTX is a drug that very specifically targets cells carrying the TRPV1 heat and pain receptors (the discovery of which led to the 2021 Nobel Prize in Medicine).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_52_5</DOCNO>
            	<TEXT>By modulating pain signaling, RTX has the potential to reduce or completely eliminate pain and the need for high dose opioids in advanced cancer patients.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_52_6</DOCNO>
            	<TEXT>SAN DIEGO, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announced that the company has received FDA clearance to proceed with a global Phase 2 clinical study of resiniferatoxin (RTX), entitled A Multicenter, Phase 2 Study to Assess the Safety and Efficacy of Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated with Advanced Cancer.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_52_7</DOCNO>
            	<TEXT>The Phase 2 trial, a multi-center, double blind, controlled study will assess the efficacy and safety of several RTX doses vs. placebo controls to manage intractable pain in up to 120 patients with advanced cancer (NCT05067257).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_52_8</DOCNO>
            	<TEXT>Three RTX dose groups (15, 20 and 25 mcg) will be evaluated against both a vehicle control group and a concurrent control group over a year of follow up.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_52_9</DOCNO>
            	<TEXT>The primary objective of the study is to identify the recommended Phase 3 dose for later studies.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_52_10</DOCNO>
            	<TEXT>The decisions related to this indication follow the analysis of the significant observations from the Phase 1b trial results (NCT03226574).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_52_11</DOCNO>
            	<TEXT>The Phase 1 was an ascending dose safety study in 17 patients to assess the safety and preliminary efficacy of epidural administration of resiniferatoxin for the treatment of intractable pain due to cancer.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_52_12</DOCNO>
            	<TEXT>RTX was generally well tolerated after epidural administration at doses up to 30 mcg with the most common adverse event of procedural pain experienced by just over half of subjects (52.9%) and all of these events were considered at most moderate severity and lasted only a few hours.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_52_13</DOCNO>
            	<TEXT>Pharmacokinetic sampling showed no measurable systemic RTX levels in nearly all subjects.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_52_14</DOCNO>
            	<TEXT>Preliminary efficacy showed promising long-standing benefit in pain reduction.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_52_15</DOCNO>
            	<TEXT>In the Phase 1 study, clinical efficacy was defined as a 30% decrease in average pain scores (CE30), calculated for both average pain for three consecutive days from original baseline score of 6 on a scale of 1 to 10 (NRS rating scale) and worst average pain, compared to baseline using the NRS during the 3 months post injection.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_52_16</DOCNO>
            	<TEXT>Eleven of 17 subjects achieved this efficacy endpoint with subjects receiving 15 or 25 mcg showing the best results.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_52_17</DOCNO>
            	<TEXT>For CE50 and CE70, 6 and 4 subjects, respectively, achieved these endpoints again with those receiving 15 or 25 mcg showing best results.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_52_18</DOCNO>
            	<TEXT>These results are promising in view of the challenging, intractable pain conditions due to advanced cancer, however the somewhat small sample size enrolled requires confirmation in larger follow-on studies. **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_52_19</DOCNO>
            	<TEXT>About Resiniferatoxin (RTX)** Resiniferatoxin is a small-molecule derivative (diterpene ester), purified from a cactus-like plant (Euphorbia sp.).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_52_20</DOCNO>
            	<TEXT>It is a highly potent agonist of the transient receptor potential vanilloid-1 (TRPV1) receptor which are specifically upregulated with chronic severe noxious pain.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_52_21</DOCNO>
            	<TEXT>A thousand times hotter than pure capsaicin (16 billion Scoville units versus 16 million), and with a high affinity for afferent sensory pain nerves, resiniferatoxin binds to TRPV1 receptors and selectively ablates the neurons responsible for perpetuating chronic severe pain signals experienced by patients.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_52_22</DOCNO>
            	<TEXT>More information on this trial can be found at [www.clinicaltrials.gov](https://www.globenewswire.com/Tracker?data=dCscyooAxBWCjl33XZvV-z0KVKYtyMZEenpOujJIRsQwKTnJEYwxSb0H-RT91TaBQKZWKYSFVu8caGQmdmgKyEyLG8LMpeSDgAEpY2RUMDM=) (NCT03542838). **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_52_23</DOCNO>
            	<TEXT>About** **Sorrento Therapeutics, Inc.**</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_53_0</DOCNO>
            	<TEXT>Our investment is looking better week by week.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_53_1</DOCNO>
            	<TEXT>Now for EUAs and/or FDA approvals and off we go!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_53_2</DOCNO>
            	<TEXT>The only fear I have at this point is with so much in the hopper, big Pharma will be salivating over the programs and pipeline.....</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_54_0</DOCNO>
            	<TEXT>Thanks for the article, which hits close to my health.. Every 6 months I get 7 to 9 injections in my lower back due to disc degeneration caused by arthritis.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_54_1</DOCNO>
            	<TEXT>I refuse oral pain meds so I suffer for about 3 months prior to my next injections twice per year.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_54_2</DOCNO>
            	<TEXT>Better treatment would be extremely welcome!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_55_0</DOCNO>
            	<TEXT>I will do that and let you know what, if any response I receive...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_56_0</DOCNO>
            	<TEXT>I will include sp-102.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_56_1</DOCNO>
            	<TEXT>Hopefully his emails aren't screened by staff..</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_57_0</DOCNO>
            	<TEXT>I have had my share of stones over the years.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_57_1</DOCNO>
            	<TEXT>I feel your pain!!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_58_0</DOCNO>
            	<TEXT>Weekly update from Sorrento</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_58_1</DOCNO>
            	<TEXT>Sorrento Therapeutics added the following items during the week of **October 11, 2021** #### All News Releases [FDA Authorizes Sorrento Phase 2 Trial of Epidural Resiniferatoxin for the Orphan Indication of Control of Intractable Cancer Pain](http://url9490.notification.gcs-web.com/ls/click?upn=Vk1mmV-2F2BYXMSdrc2O0yE3dIdyJ36Qf-2BrVD74w8Wyr-2BJYIQfsy88dcRAv-2F2EJ6vIET4GgcfBMIk9tSVDdAPZV9Bcyz5l0t5Y1tg68Epn-2BsI8QxtGBmz75-2FzrtgMM0jffRfofarE7d7JGprS4QS9JKOQrcYZyBG0pNXS8N7-2BM-2FvmriLdYHCHWOPGaIJFsRYKjWkdKBMrT2geK8ofKpb7NNA-3D-3DrvmH_DKMwEV5rE6ItJiX8ruKGZFPAKW3-2FBj8orHheDZHS-2F07idJuKH6yPcaZWWj7xUPGGPC6Gq4HexP52qBH7hRAtUAmWNV16tgY6i3WUkkp8-2FHlEvpaYLARQOz5zs6m6Nros6e41HIn1mC2UBy07Lt6HKo9MyRoXNi3xkjaBwGB-2BHe-2B9Pq3iZLAvOoaXyETZQRSNSNFi-2BOsnMkMBi82fVIfx36wapec3Fz4rd5QgRJo1BsxceDyE8o9Bb-2FupPC8cuqlLJWDkssYegxyDseRiThynJg-3D-3D) [Sorrento Receives FDA Clearance to Proceed With Clinical Trial for Anti-TROP-2 Antibody Drug Conjugate (TROP-2 ADC) for multiple solid tumors](http://url9490.notification.gcs-web.com/ls/click?upn=Vk1mmV-2F2BYXMSdrc2O0yE3dIdyJ36Qf-2BrVD74w8Wyr-2BJYIQfsy88dcRAv-2F2EJ6vIET4GgcfBMIk9tSVDdAPZV9Bcyz5l0t5Y1tg68Epn-2BsIniftGSna5j50r4rl488oviz3MSvpf0mjdBttM3o-2BwrIe82Da9zE2q632R94oUSHqDbcjy5Xvj5tWui0RKKuSQktiwa-2BeoWsz4nKsLRe8m-2FQ-3D-3Dy4wb_DKMwEV5rE6ItJiX8ruKGZFPAKW3-2FBj8orHheDZHS-2F07idJuKH6yPcaZWWj7xUPGGPC6Gq4HexP52qBH7hRAtUAmWNV16tgY6i3WUkkp8-2FHlEvpaYLARQOz5zs6m6NrosOKsL4qfiSkUXIQx2a0Nbk1dGlaGFLqgoNeD3a69tu7mVxRU7oUxTwsRG-2FdqbmM5tp3BWjqf3GyiqtxZxN-2FloPymqwohMNjV2yrBAreU-2Fvft6WEOCnSKnOc-2BxHFv4nlkLhoa2U61NMJkb2QzpnyxAxQ-3D-3D)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_59_0</DOCNO>
            	<TEXT>FDA weekly update</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_59_1</DOCNO>
            	<TEXT># [Coronavirus (COVID-19) Update: Oct.15, 2021](https://lnks.gd/l/eyJhbGciOiJIUzI1NiJ9.eyJidWxsZXRpbl9saW5rX2lkIjoxMDEsInVyaSI6ImJwMjpjbGljayIsImJ1bGxldGluX2lkIjoiMjAyMTEwMTUuNDc0NDQzNjEiLCJ1cmwiOiJodHRwczovL3d3dy5mZGEuZ292L25ld3MtZXZlbnRzL3ByZXNzLWFubm91bmNlbWVudHMvY29yb25hdmlydXMtY292aWQtMTktdXBkYXRlLTEwMTUyMT91dG1fbWVkaXVtPWVtYWlsJnV0bV9zb3VyY2U9Z292ZGVsaXZlcnkifQ.dQgpTmPwyuQjDwT1ag6Jz_4QIwQ2HVE0bl2JsXcI4bw/s/1419462572/br/114032994309-l) The U.S. Food and Drug Administration (FDA) continued to take action in the ongoing response to the COVID-19 pandemic: * On Oct. 12, the FDA posted information about an assessment of the Emergency Use Authorization (EUA) process that the FDAs Center for Devices and Radiological Health (CDRH) implemented to help authorize COVID-19 tests during the public health emergency.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_59_2</DOCNO>
            	<TEXT>The assessment was conducted by Booz Allen Hamilton, an independent, third-party contractor.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_59_3</DOCNO>
            	<TEXT>This assessment focuses on how CDRH prioritized processing of EUA requests, review times, accuracy and reliability of COVID-19 tests, a comparison to prior public health emergencies and requestors perspectives.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_59_4</DOCNO>
            	<TEXT>The [web posting](https://lnks.gd/l/eyJhbGciOiJIUzI1NiJ9.eyJidWxsZXRpbl9saW5rX2lkIjoxMDIsInVyaSI6ImJwMjpjbGljayIsImJ1bGxldGluX2lkIjoiMjAyMTEwMTUuNDc0NDQzNjEiLCJ1cmwiOiJodHRwczovL3d3dy5mZGEuZ292L21lZGljYWwtZGV2aWNlcy9jb3JvbmF2aXJ1cy1jb3ZpZC0xOS1hbmQtbWVkaWNhbC1kZXZpY2VzL2VtZXJnZW5jeS11c2UtYXV0aG9yaXphdGlvbi1jb3ZpZC0xOS10ZXN0cy1pbmRlcGVuZGVudC1hc3Nlc3NtZW50LWZkYXMtcmVzcG9uc2U_dXRtX21lZGl1bT1lbWFpbCZ1dG1fc291cmNlPWdvdmRlbGl2ZXJ5In0.Fe233P1tsmIaW8nOKAGeKc1wwWPhPyqc2IcUoQ2Pkgw/s/1419462572/br/114032994309-l) includes Booz Allen Hamiltons Emergency Use Authorization Assessment and recommendations and CDRHs perspectives and next steps. *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_59_5</DOCNO>
            	<TEXT>The Center for Food Safety and Applied Nutrition published a [Constituent Update](https://lnks.gd/l/eyJhbGciOiJIUzI1NiJ9.eyJidWxsZXRpbl9saW5rX2lkIjoxMDMsInVyaSI6ImJwMjpjbGljayIsImJ1bGxldGluX2lkIjoiMjAyMTEwMTUuNDc0NDQzNjEiLCJ1cmwiOiJodHRwczovL3d3dy5mZGEuZ292L2Zvb2QvY2ZzYW4tY29uc3RpdHVlbnQtdXBkYXRlcy9mZGEtZW5jb3VyYWdlcy1mb29kLWFuZC1hZ3JpY3VsdHVyZS13b3JrZXJzLWdldC12YWNjaW5hdGVkLWFnYWluc3QtZmx1LWFuZC1jb3ZpZC0xOT91dG1fbWVkaXVtPWVtYWlsJnV0bV9zb3VyY2U9Z292ZGVsaXZlcnkifQ.XthtbS-b17350Hxv1dEcXoD_Bsmvj2ghLhHDwcZRKro/s/1419462572/br/114032994309-l) intended for food and agriculture workers/industry encouraging vaccination against influenza and COVID-19. *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_59_6</DOCNO>
            	<TEXT>Testing updates: * As of today, 418 tests and sample collection devices are authorized by the FDA under emergency use authorizations (EUAs).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_59_7</DOCNO>
            	<TEXT>These include 292 molecular tests and sample collection devices, 89 antibody and other immune response tests and 37 antigen tests.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_59_8</DOCNO>
            	<TEXT>There are 66 molecular authorizations and one antibody authorization that can be used with home-collected samples.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_59_9</DOCNO>
            	<TEXT>There is one molecular prescription at-home test, three antigen prescription at-home tests, seven antigen over-the-counter (OTC) at-home tests and two molecular OTC at-home tests. *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_59_10</DOCNO>
            	<TEXT>The FDA has authorized 16 antigen tests and eight molecular tests for serial screening programs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_59_11</DOCNO>
            	<TEXT>The FDA has also authorized 650 revisions to EUA authorizations. [**</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_59_12</DOCNO>
            	<TEXT>Coronavirus Disease 2019 (COVID-19)**](https://lnks.gd/l/eyJhbGciOiJIUzI1NiJ9.eyJidWxsZXRpbl9saW5rX2lkIjoxMDQsInVyaSI6ImJwMjpjbGljayIsImJ1bGxldGluX2lkIjoiMjAyMTEwMTUuNDc0NDQzNjEiLCJ1cmwiOiJodHRwczovL3d3dy5mZGEuZ292L2VtZXJnZW5jeS1wcmVwYXJlZG5lc3MtYW5kLXJlc3BvbnNlL2NvdW50ZXJ0ZXJyb3Jpc20tYW5kLWVtZXJnaW5nLXRocmVhdHMvY29yb25hdmlydXMtZGlzZWFzZS0yMDE5LWNvdmlkLTE5P3V0bV9tZWRpdW09ZW1haWwmdXRtX3NvdXJjZT1nb3ZkZWxpdmVyeSJ9.mw0K2VWECRf99-xHRi5zu6_GH7_E-pnBH6lE5IuFmls/s/1419462572/br/114032994309-l)[**COVID-19 Vaccines**](https://lnks.gd/l/eyJhbGciOiJIUzI1NiJ9.eyJidWxsZXRpbl9saW5rX2lkIjoxMDUsInVyaSI6ImJwMjpjbGljayIsImJ1bGxldGluX2lkIjoiMjAyMTEwMTUuNDc0NDQzNjEiLCJ1cmwiOiJodHRwczovL3d3dy5mZGEuZ292L2VtZXJnZW5jeS1wcmVwYXJlZG5lc3MtYW5kLXJlc3BvbnNlL2Nvcm9uYXZpcnVzLWRpc2Vhc2UtMjAxOS1jb3ZpZC0xOS9jb3ZpZC0xOS12YWNjaW5lcz91dG1fbWVkaXVtPWVtYWlsJnV0bV9zb3VyY2U9Z292ZGVsaXZlcnkifQ.TG5NkQMGEYrxIYsUwPLqXuvPCToLfBirUKgVFpClf1U/s/1419462572/br/114032994309-l)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_60_0</DOCNO>
            	<TEXT>The FDA and Big Pharma!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_60_1</DOCNO>
            	<TEXT>**How is the pharmaceutical industry making its inroads into the FDA?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_60_2</DOCNO>
            	<TEXT>Where is it exerting its influence?**</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_60_3</DOCNO>
            	<TEXT>The pharmaceutical industry's influence gets exerted in a number of ways.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_60_4</DOCNO>
            	<TEXT>One, starting 10 years ago \[with the Prescription Drug User Fee Act (PDUFA)\], the influence was exerted by their directly funding, paying cash right up front, for FDA review.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_60_5</DOCNO>
            	<TEXT>So in many ways, the FDA started looking upon the industry as their client, instead of the public and the public health, which should be the client.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_60_6</DOCNO>
            	<TEXT>The FDA is an agency of the Public Health Service.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_60_7</DOCNO>
            	<TEXT>Its primary mission is to improve the public health.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_60_8</DOCNO>
            	<TEXT>You have to be very cautious when -- through a combination of being funded directly by the industry, as opposed to through the U.S. Treasury, and congressional influences which are pro-industry as opposed to pro-consumer -- it starts moving in a way that is very favorable to the industry.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_60_9</DOCNO>
            	<TEXT>The FDA, obviously, has to work with the industry, and that's good.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_60_10</DOCNO>
            	<TEXT>But when the FDA starts getting taken over in many ways by the industry, that's not good.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_60_11</DOCNO>
            	<TEXT>In response to the questionnaire that we sent out to the physicians at the FDA, they themselves told us that, many times, they believe that industry influence was operating on the people above them, and getting their bosses to overturn some of the decisions that they had made against approving a drug.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_60_12</DOCNO>
            	<TEXT>So there are lots of sources of evidence about the fact that the pharmaceutical industry has an almost unprecedented finger or thumb on the FDA in the last few years, compared with any time in the past. ...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_60_13</DOCNO>
            	<TEXT>W**hat's the concept \[of user fees\]?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_60_14</DOCNO>
            	<TEXT>How does it work?**</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_60_15</DOCNO>
            	<TEXT>For the first 86 years of FDA's existence, from 1906-1992, all of FDA's funding came through the U.S. Treasury.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_60_16</DOCNO>
            	<TEXT>In other words, everyone -- industry, people -- paid their taxes, and FDA got appropriations out of the budget.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_60_17</DOCNO>
            	<TEXT>Starting in 1992, unfortunately, a law was passed that said for a large proportion of the work done by the FDA on new drug applications, the money's going to come directly, quid pro quo, from the industry.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_60_18</DOCNO>
            	<TEXT>If they want a drug reviewed, they pay directly to the FDA to have the drug reviewed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_60_19</DOCNO>
            	<TEXT>This system has created a very unhealthy relationship -- even more unhealthy than it used to be -- between the industry and the FDA, where the FDA says, "We have to be nice to these people, because they are paying our bills."</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_60_20</DOCNO>
            	<TEXT>It's developed an unhealthy sort of client relationship between the government and the industry which, I think, has resulted in some drugs getting approved that shouldn't; drugs being put on a faster track than they should have.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_60_21</DOCNO>
            	<TEXT>I think that, in general, it's been a very bad idea.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_60_22</DOCNO>
            	<TEXT>We strongly favor ending this experiment, which has had, in the 10 years that it's been in existence, some of the worst things happen in terms of drug safety we've ever seen.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_60_23</DOCNO>
            	<TEXT>I think that's not the only explanation.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_60_24</DOCNO>
            	<TEXT>But direct cash funding from the pharmaceutical industry to the FDA turns out to be a very bad idea.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_61_0</DOCNO>
            	<TEXT>Welcome, we look forward to your posts and opinions...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_62_0</DOCNO>
            	<TEXT>I am a walking example of this off label use of injectable corticosteroids.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_62_1</DOCNO>
            	<TEXT>Twice per year I receive 7 to 9 injections into my lower back and also receive the epidural, which is very painful!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_62_2</DOCNO>
            	<TEXT>Will look forward to a safer method of treatment..</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_63_0</DOCNO>
            	<TEXT>We have lost another great American Patriot who should and will be honored.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_63_1</DOCNO>
            	<TEXT>Could he and other have been saved with the best treatments possible?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_63_2</DOCNO>
            	<TEXT>Unfortunately, we will never know.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_63_3</DOCNO>
            	<TEXT>Until the FDA returns to being truly an independent entity and not an arm of big pharma more and more lives will be lost which could have been saved, tragic!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_64_0</DOCNO>
            	<TEXT>Coincidence, maybe, but sometimes there are other forces having a hand it what takes place.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_64_1</DOCNO>
            	<TEXT>Regardless, progress taking place on all fronts....</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_65_0</DOCNO>
            	<TEXT>The yahoo gremlins at work!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_66_0</DOCNO>
            	<TEXT>No, but I did post a message in response..</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_67_0</DOCNO>
            	<TEXT>Yahoo is blocking anything I try to post1</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_68_0</DOCNO>
            	<TEXT>I see your post, thanks for breaking through the yahoo wall!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_68_1</DOCNO>
            	<TEXT>That response was from don not Don.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_68_2</DOCNO>
            	<TEXT>Small case d is the posts of a small don in credibility!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_69_0</DOCNO>
            	<TEXT>Very sad when any individual is unable to search their heart and care that we lost such a hero....</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_70_0</DOCNO>
            	<TEXT>Makes me wonder who Paul really is as a person, not as an ID...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_71_0</DOCNO>
            	<TEXT># News Release # Sorrento Announces That COVISTIX (COVID-19 Virus Rapid Antigen Detection Test) Has Received a CE Mark and Registration of the Device October 20, 2021 at 1:37 PM EDT[Download PDF](https://investors.sorrentotherapeutics.com/node/12741/pdf) * COVISTIX has received CE mark and marketing authorization from FAMHP (Federal Agency for Medicines and Health Products) that enables Sorrento to sell this device in all territories that accept the Qarad EC-Rep (Belgium) CE Mark for commercialization. *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_71_1</DOCNO>
            	<TEXT>Distribution contracts are being negotiated.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_71_2</DOCNO>
            	<TEXT>SAN DIEGO, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that it has received an official CE Mark for COVISTIX and a Registration Number: BE/CA01/1-17633-00001-IVD.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_71_3</DOCNO>
            	<TEXT>COVISTIX is a sensitive and rapid (approximately 15-minute) diagnostic test for the detection of the SARS-CoV-2 virus nucleocapsid antigen in nasal or nasopharyngeal samples of patients suspected of a SARS-CoV-2 infection.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_71_4</DOCNO>
            	<TEXT>COVISTIX is currently EUA-cleared in Mexico by COFEPRIS and EUA filings are underway with Canada, Brazil, WHO, and the US.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_71_5</DOCNO>
            	<TEXT>In a large independent study conducted by INMEGEN (The Instituto Nacional de Medicina Genomica, Mexico), COVISTIX demonstrated high accuracy as a general screening for all-comers (*i.e.*COVID-19 symptomatic and asymptomatic populations), COVISTIX (n=783) has an 81% sensitivity vs. 62% (n=2202) sensitivity by globally leading Panbio rapid antigen test.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_71_6</DOCNO>
            	<TEXT>Sorrento is currently negotiating with global and regional distributors to ensure rapid distribution of COVISTIX to those countries that access to rapid, accurate and affordable testing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_71_7</DOCNO>
            	<TEXT>This is a significant milestone for Sorrento and we appreciate the cooperation with European authorities to bring our highly sensitive antigen test to help control this pandemic, stated Dr. Henry Ji, Chairman and CEO of Sorrento.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_71_8</DOCNO>
            	<TEXT>We are expanding our manufacturing capacity in anticipation of large orders and are ready to deliver tests in the tens of millions of units.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_72_0</DOCNO>
            	<TEXT>I agree, you may get picked off at first while trying to get too much of a lead instead of waiting for the batter to move you to 2nd or third.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_72_1</DOCNO>
            	<TEXT>You should stay on third, second, first, or even in the dugout and waited for the glorious grand-slam to win the game in the bottom of the 9th!!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_72_2</DOCNO>
            	<TEXT>It's coming, we may be only in the 4th or 5th inning, but I believe we are having the 7th inning stretch!!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_72_3</DOCNO>
            	<TEXT>We may even have a rain delay, but it will be a victory for all who wait it out...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_73_0</DOCNO>
            	<TEXT>Big Pharma in the making!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_73_1</DOCNO>
            	<TEXT>Sorrento is a "Big Pharma" in the making being held at a ridiculously low small bio price.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_73_2</DOCNO>
            	<TEXT>This will not remain at these bargain prices for long.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_73_3</DOCNO>
            	<TEXT>Without doubt the opportunity of a lifetime for those who are loading up shares and are willing to wait for the inevitable Big Pharma to come of age.. As Dr Ji warned the 'shorts'" do not ruin your families".</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_73_4</DOCNO>
            	<TEXT>Check out Don's post earlier today. "</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_73_5</DOCNO>
            	<TEXT>Why am I loaded up with SRNE".</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_73_6</DOCNO>
            	<TEXT>Find it on yahoo.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_74_0</DOCNO>
            	<TEXT>Nice to see more and more articles and reports mentioning Sorrento.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_74_1</DOCNO>
            	<TEXT>The more exposure we receive, the more interest is created resulting in more and more investors, big and small.. One step at a time, always forward.....</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_75_0</DOCNO>
            	<TEXT>The Weekend Is here...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_75_1</DOCNO>
            	<TEXT>The weekend is here, time to relax and watch some football!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_75_2</DOCNO>
            	<TEXT>Saturday's NCAA games of interest to me.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_75_3</DOCNO>
            	<TEXT>Only a few good match-ups this week.. Clem at Pitts, LSU at Ole Miss, Ore at UCLA, SD ST at AF Thoughts?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_75_4</DOCNO>
            	<TEXT>I will be placing my 10 parlay bets this evening.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_75_5</DOCNO>
            	<TEXT>A 2 game parlay bet of $10 pays an avg of $25, makes the games more interesting... I only have to win 3 out of the 10 to break even, and always do better than that...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_76_0</DOCNO>
            	<TEXT>My straight up picks of the winners of these 4 games are Clem, Ole Miss, Ore and SD ST.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_76_1</DOCNO>
            	<TEXT>The top rated Schools all have easy wins this week.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_76_2</DOCNO>
            	<TEXT>Tenn might hang in with Ala in the first quarter or even to half time as may NW at Mich... A late game may be a decent one, USC at ND....</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_77_0</DOCNO>
            	<TEXT>Very interesting that there has not been any talk of the flu this season, not even urgings to get the flu shot.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_77_1</DOCNO>
            	<TEXT>The CDC site's flu report is of only 2 sentences. "</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_77_2</DOCNO>
            	<TEXT>Laboratory-confirmed flu activity is low at this time".</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_77_3</DOCNO>
            	<TEXT>and, "A COVID-19-pandemic is ongoing".</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_78_0</DOCNO>
            	<TEXT>I try to repost...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_79_0</DOCNO>
            	<TEXT>Let's see if it stays......</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_80_0</DOCNO>
            	<TEXT>Looks like it's been removed already!!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_81_0</DOCNO>
            	<TEXT>3 re-post tries and all removed!!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_82_0</DOCNO>
            	<TEXT>I even tried it without the links..</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_83_0</DOCNO>
            	<TEXT>I tried to post something else with no success.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_83_1</DOCNO>
            	<TEXT>Somehow I'm blocked from posting on yahoo!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_84_0</DOCNO>
            	<TEXT>Most likely due to repeatedly posting your toxic post, LOL!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_85_0</DOCNO>
            	<TEXT>Jim, you want me to send it how?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_86_0</DOCNO>
            	<TEXT>They don't even take Sundays off!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_87_0</DOCNO>
            	<TEXT>I don't watch much pro football but my Titan's are eating KC's lunch!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_88_0</DOCNO>
            	<TEXT>Bringing on a top PR person will be very beneficial to the investors and the stock itself.. Sorrento and Dr Ji are making this move at the right time in the growth of the company.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_88_1</DOCNO>
            	<TEXT>Smart addition to great mgmt team, forward one step at a time.....</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_89_0</DOCNO>
            	<TEXT>FDA authorized more at home test kits.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_89_1</DOCNO>
            	<TEXT># [Coronavirus (COVID-19) Update: Oct. 26, 2021](https://lnks.gd/l/eyJhbGciOiJIUzI1NiJ9.eyJidWxsZXRpbl9saW5rX2lkIjoxMDEsInVyaSI6ImJwMjpjbGljayIsImJ1bGxldGluX2lkIjoiMjAyMTEwMjYuNDc5Mjg0MDEiLCJ1cmwiOiJodHRwczovL3d3dy5mZGEuZ292L25ld3MtZXZlbnRzL3ByZXNzLWFubm91bmNlbWVudHMvY29yb25hdmlydXMtY292aWQtMTktdXBkYXRlLW9jdG9iZXItMjYtMjAyMT91dG1fbWVkaXVtPWVtYWlsJnV0bV9zb3VyY2U9Z292ZGVsaXZlcnkifQ.U_A3UairPyovKA4JYmYu9PNfvfkbRtPdgA8uZEDOrbg/s/1419462572/br/114668149716-l) The U.S. Food and Drug Administration (FDA) continued to take action in the ongoing response to the COVID-19 pandemic: The FDA authorized the 10th over-the-counter (OTC) COVID-19 test, reissued the emergency use authorization (EUA) for another OTC COVID-19 test, and updated the EUA templates for test developers seeking an EUA for OTC tests.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_89_2</DOCNO>
            	<TEXT>The FDA: * Issued an EUA for the [Celltrion DiaTrust COVID-19 Ag Home Test](https://lnks.gd/l/eyJhbGciOiJIUzI1NiJ9.eyJidWxsZXRpbl9saW5rX2lkIjoxMDIsInVyaSI6ImJwMjpjbGljayIsImJ1bGxldGluX2lkIjoiMjAyMTEwMjYuNDc5Mjg0MDEiLCJ1cmwiOiJodHRwczovL3d3dy5mZGEuZ292L21lZGlhLzE1MzQxOC9kb3dubG9hZD91dG1fbWVkaXVtPWVtYWlsJnV0bV9zb3VyY2U9Z292ZGVsaXZlcnkifQ.u0Yd4tl-M3p8uxqQ2Os3HH8JXfmgqkl2pk6N9XMRFvo/s/1419462572/br/114668149716-l), an OTC COVID-19 diagnostic antigen test.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_89_3</DOCNO>
            	<TEXT>The test can be used by people with COVID-19 symptoms as a single test without a health care provider prescription or by people with or without symptoms for serial testing, which means the test is performed two times over three days. *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_89_4</DOCNO>
            	<TEXT>Reissued the EUA for the [Quidel QuickVue At-Home OTC COVID-19 Test](https://lnks.gd/l/eyJhbGciOiJIUzI1NiJ9.eyJidWxsZXRpbl9saW5rX2lkIjoxMDMsInVyaSI6ImJwMjpjbGljayIsImJ1bGxldGluX2lkIjoiMjAyMTEwMjYuNDc5Mjg0MDEiLCJ1cmwiOiJodHRwczovL3d3dy5mZGEuZ292L21lZGlhLzE0NzI0Ny9kb3dubG9hZD91dG1fbWVkaXVtPWVtYWlsJnV0bV9zb3VyY2U9Z292ZGVsaXZlcnkifQ.gWMtcB4N1ahkpa2ZBxi3URh5q7ogtqmLxU7O9ZwgZi8/s/1419462572/br/114668149716-l) to authorize use by people with COVID-19 symptoms as a single test without a health care provider prescription.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_89_5</DOCNO>
            	<TEXT>The test is already authorized for use by people with or without symptoms as a serial test and for people with COVID-19 symptoms as a single test with a health care provider prescription. *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_89_6</DOCNO>
            	<TEXT>Updated the test labeling recommendations for test instructions and product labeling in the EUA templates for test developers to support authorization of more COVID-19 tests for use without a health care provider prescription.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_89_7</DOCNO>
            	<TEXT>The updated templates also include flexible study recommendations about how to demonstrate that different types and ages of consumers can use the test appropriately.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_89_8</DOCNO>
            	<TEXT>These updated templates include the following: * [Molecular and Antigen Home Use Test Template](https://lnks.gd/l/eyJhbGciOiJIUzI1NiJ9.eyJidWxsZXRpbl9saW5rX2lkIjoxMDQsInVyaSI6ImJwMjpjbGljayIsImJ1bGxldGluX2lkIjoiMjAyMTEwMjYuNDc5Mjg0MDEiLCJ1cmwiOiJodHRwczovL3d3dy5mZGEuZ292L21lZGlhLzE0MDYxNS9kb3dubG9hZD91dG1fbWVkaXVtPWVtYWlsJnV0bV9zb3VyY2U9Z292ZGVsaXZlcnkifQ.qlmIYhyMWMyyWMaNDtQt8O3_k10P2y6_hIdxeHVj8PM/s/1419462572/br/114668149716-l) * [Supplemental Template for Molecular and Antigen Diagnostic COVID-19 Tests for Screening with Serial Testing](https://lnks.gd/l/eyJhbGciOiJIUzI1NiJ9.eyJidWxsZXRpbl9saW5rX2lkIjoxMDUsInVyaSI6ImJwMjpjbGljayIsImJ1bGxldGluX2lkIjoiMjAyMTEwMjYuNDc5Mjg0MDEiLCJ1cmwiOiJodHRwczovL3d3dy5mZGEuZ292L21lZGlhLzE0NjY5NS9kb3dubG9hZD91dG1fbWVkaXVtPWVtYWlsJnV0bV9zb3VyY2U9Z292ZGVsaXZlcnkifQ.vz8AZVm4a_fjv_MW2_Ekeha68m3SD5IdjImsLfhh0iE/s/1419462572/br/114668149716-l)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_90_0</DOCNO>
            	<TEXT>Abivertinib results</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_90_1</DOCNO>
            	<TEXT># News Release # Sorrento Announces Encouraging Results From Two Phase 2 Studies of Abivertinib For Treatment Of Hospitalized Severe COVID-19 Patients October 27, 2021 at 2:26 PM EDT[Download PDF](https://investors.sorrentotherapeutics.com/node/12746/pdf) * Abivertinib is an oral capsule (100 mg QD or two 50-mg capsules a day) that potentially reduces cytokine storm associated with acute respiratory distress syndrome (ARDS) in severe hospitalized COVID-19 patients. *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_90_2</DOCNO>
            	<TEXT>Preliminary results from two completed Phase 2 studies: US study (N=96) and Brazil study (N=400) have identified an **At-Risk COVID-19 Patient Population** \- **Hospitalized** **COVID patients receiving oxygen support by non-invasive ventilation or high flow oxygen** \- which can potentially benefit from Abivertinib treatment. *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_90_3</DOCNO>
            	<TEXT>The At-Risk COVID-19 Patients show a reduction (20% reduction in the US study and 25% in the Brazil study, respectively) in death or respiratory failure at one month time point. *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_90_4</DOCNO>
            	<TEXT>The At-Risk Patients in the US study (who were a sicker population than those in the Brazilian study) were discharged on average 2 days sooner from the ICU. *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_90_5</DOCNO>
            	<TEXT>Abivertinib has the potential to fill the unmet need for the At-Risk COVID-19 Patients and significantly reduce progression to intubation, mechanical ventilation and death.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_90_6</DOCNO>
            	<TEXT>SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announcedtodaypositive preliminaryresultsfrom two Phase 2 studies designed to identify the hospitalized patient population suffering from COVID-19-induced pneumonia and respiratory depression likely to respond to treatment with oral Abivertinib.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_90_7</DOCNO>
            	<TEXT>Abivertinib is a novel small molecule tyrosine kinase inhibitor (TKI) that selectively targets both mutant forms of the epidermal growth factor receptor (EGFR) as well as Bruton's tyrosine kinase (BTK).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_90_8</DOCNO>
            	<TEXT>Abivertinib irreversibly binds to the BTK receptor, preventing the phosphorylation of the receptor.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_90_9</DOCNO>
            	<TEXT>Due to this effect, it has shown potent immunomodulatory activities *in vitro* with potent inhibition of key pro-inflammatory cytokine production, including IL-1 beta, IL-6 and TNF-alpha.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_90_10</DOCNO>
            	<TEXT>These cytokines are associated with acute respiratory distress syndrome (ARDS), and with cytokine release syndrome (CRS) or cytokine storm, and COVID-19 disease progression with poor outcomes in patients.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_90_11</DOCNO>
            	<TEXT>The US study, entitled A Phase 2, Double Blinded, Randomized Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) With Standard of Care Versus Standard of Care in Subjects Hospitalized With COVID-19 (NCT04440007), recently completed enrollment (N=96 randomized 1:1).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_90_12</DOCNO>
            	<TEXT>The Brazil study, entitled A Phase 2, Randomized, Double-Blind, Placebo-controlled Study of the Safety and Efficacy of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized Due to COVID-19 also completed enrollment (N=400, randomized 3:1 active vs. placebo).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_90_13</DOCNO>
            	<TEXT>Both studies were designed to assess the potential clinical benefits of Abivertinibs ability to reduce inflammatory cytokine storm associated with COVID-19-induced respiratory depression.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_90_14</DOCNO>
            	<TEXT>It was also important to identify the potential patient population most likely to respond to treatment based upon severity of COVID-19 respiratory depression at baseline.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_90_15</DOCNO>
            	<TEXT>In both studies the clinical status was assessed using a 9-point (0 to 8) categorical scale, where 3=hospitalized with no oxygen therapy, 4=hospitalized with oxygen by mask or nasal cannulae, 5=non-invasive ventilation or high flow oxygen, 6=intubation and mechanical ventilation, 7=additional organ support such as extracorporeal membrane oxygenation, and 8=death. **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_90_16</DOCNO>
            	<TEXT>Brazilian Protocol DesignU.S.Protocol Design**Mild, Moderate and Severe COVID-19 patientsSevere COVID-19 patientsAny hospitalized patientICU non-ventilated**N=400** randomized 3:1 (Abivertinib to placebo); stratified for COVID-19 severity at baseline**N=96**randomized 1:1 (Abivertinib to placebo)**100 mg** QD x**7**days**100 mg** QD x**14 days or discharge if sooner**All patients received standard of care treatment for COVID-19All patients received standard of care treatment for COVID-19Duration 65 daysDuration 94 daysPrimary endpoint: %**alive**and discharged at one monthPrimary endpoint: %**alive**and free of respiratory failure at one monthNCT 04528667 ANVISA (Brazilian authority) under Process n**25351.105670/2020-14**, Reference n**3380614/20-4**NCT 04440007 In the US Abivertinib study, most patients (57%) were sicker at baseline (category 5 clinical status) with patients in the Abivertinib group skewed to sicker or worse severity by clinical status (Abivertinib Group: 29/48: 60% vs. Control Placebo Group: 26/48: 38% for category 5, respectively) and by oxygenation status (P/F ratio 211 vs. 253, respectively).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_90_17</DOCNO>
            	<TEXT>In the Brazil Abivertinib study, only 8% were in category 5, demonstrating a far less severely compromised population having been enrolled.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_90_18</DOCNO>
            	<TEXT>In the US study, patients in category 5 showed a 20% improvement in the primary endpoint, and in the Brazil study, a 25% improvement.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_90_19</DOCNO>
            	<TEXT>In the US study, patients in category 5 treated with Abivertinib were discharged from the hospital 2 days sooner than those in the Control Group (8.6 vs. 10.6 days).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_90_20</DOCNO>
            	<TEXT>Overall, in both studies patients who were in category 5, but not in category  lt; 4, showed improvement with Abivertinib treatment.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_90_21</DOCNO>
            	<TEXT>Based upon these preliminary results, a pivotal multi-country, multi-center pivotal Phase 3 study is being planned in 400 patients (randomized 1:1) on the At-Risk Hospitalized COVID-19 Patients requiring oxygen support via non-invasive ventilation or high flow oxygen at baseline (category 5 patients).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_90_22</DOCNO>
            	<TEXT>Patients on non-invasive ventilation or high flow oxygen supplementation due to COVID-19-induced respiratory failure represent a sicker and at-risk population with few available treatment options, stated Dr.Mike Royal, Chief Medical Officer ofSorrento Therapeutics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_90_23</DOCNO>
            	<TEXT>Abivertinib has the potential to fill this unmet need and significantly reduce progression to intubation, mechanical ventilation and death.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_91_0</DOCNO>
            	<TEXT>You are right, until revenues come in the 'shorts' will be able to keep the share price in a deflated range.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_91_1</DOCNO>
            	<TEXT>Price rises to 7.18 and taken down almost 7%.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_91_2</DOCNO>
            	<TEXT>All these positive news releases will pile up and when revenues do begin to come in the stock will rise rapidly and the remaining shorts will be slaughtered while trying to all cover at once...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_92_0</DOCNO>
            	<TEXT>Thank you, today's sermon is excellent and spot on..</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_93_0</DOCNO>
            	<TEXT>The mods over there are disgusting.. I have now left the site and blocked all notifications from them... Ariad.... and his many IDs are probably the mods!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_94_0</DOCNO>
            	<TEXT>I am done with them and will not post or view the board.....</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_95_0</DOCNO>
            	<TEXT>The most accurate and reliable numbers, not self reported by the firms but from the stock exchanges...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_96_0</DOCNO>
            	<TEXT>Excellent point on explanation..</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_97_0</DOCNO>
            	<TEXT>The failure and/or the disappointment of other competitive forms of treatment should propel Abivertinib to become the standard of care.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_97_1</DOCNO>
            	<TEXT>and as Don mentioned, " how about Abivertinib and COVID-MSC combinations"....</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_98_0</DOCNO>
            	<TEXT>I am doing the same...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_99_0</DOCNO>
            	<TEXT>A daily morning prayer would be more than appropriate.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_99_1</DOCNO>
            	<TEXT>Those who choose not to take part have that choice to not open the post.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_99_2</DOCNO>
            	<TEXT>We are losing our freedoms almost daily in this country and unfortunately it may be too late to reverse this disgusting trend...... Thank you.....</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_100_0</DOCNO>
            	<TEXT>Getting more and more recognition.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_100_1</DOCNO>
            	<TEXT>One step at a time in the right direction. "</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_100_2</DOCNO>
            	<TEXT>Another brick in the wall"....</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_101_0</DOCNO>
            	<TEXT>Sorrento weekly report</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_101_1</DOCNO>
            	<TEXT>Sorrento Therapeutics added the following items during the week of **October 25, 2021** #### All News Releases [Sorrento Announces Encouraging Results From Two Phase 2 Studies of Abivertinib For Treatment Of Hospitalized Severe COVID-19 Patients](http://url9490.notification.gcs-web.com/ls/click?upn=Vk1mmV-2F2BYXMSdrc2O0yE3dIdyJ36Qf-2BrVD74w8Wyr-2BJYIQfsy88dcRAv-2F2EJ6vIET4GgcfBMIk9tSVDdAPZV9Bcyz5l0t5Y1tg68Epn-2BsJxt2Qa7HN8Nuu46WqV7VpkQcaCyzsN1ttlTDw5YKceb4Hsb8IZgRGj7-2F75dQoYAtweP3Ej1hri6DqnlScXElyWpjzI6EGGSupWQQULLqPSlg-3D-3DM9cb_DKMwEV5rE6ItJiX8ruKGZFPAKW3-2FBj8orHheDZHS-2F07idJuKH6yPcaZWWj7xUPGGlHXGNKJqV9oSs967iv0vw89O3cRiRwcb07wRyh58beDcAfHIXEn9k4Dd9M3gL5KA8gQGM14hnu44ON6Y3TB8z5HZt3111b6kjEyS50yKBsJKCrSzmBtPwliLUgnAp0Qs6UnTIBYC4Egk90K8zrBEvG61kT4QhdVBf9JmVw9FCrMN3k7Rk2VUutHe3MiLsSNfsNDvenIwjuG50xZMcEAFgA-3D-3D) [UPDATE Sorrento Announces Encouraging Results From Two Phase 2 Studies of Abivertinib For Treatment Of Hospitalized Severe COVID-19 Patients](http://url9490.notification.gcs-web.com/ls/click?upn=Vk1mmV-2F2BYXMSdrc2O0yE3dIdyJ36Qf-2BrVD74w8Wyr-2BJYIQfsy88dcRAv-2F2EJ6vIET4GgcfBMIk9tSVDdAPZV9Bcyz5l0t5Y1tg68Epn-2BsKajQswJMjzyKTpg9lEyYCjSe02iEzcGXL-2Fj1Uc5ivkpwQUGU44gbqOvRU6Ii5SkHQy5zpTWwv0jY4NvTq9fdaVaJf__DKMwEV5rE6ItJiX8ruKGZFPAKW3-2FBj8orHheDZHS-2F07idJuKH6yPcaZWWj7xUPGGlHXGNKJqV9oSs967iv0vw89O3cRiRwcb07wRyh58beDcAfHIXEn9k4Dd9M3gL5KAn9cAM4nUMl-2Bwl6ISCz2G9LauGmHZ9bKr8mLIuzSDbV89xYfCyLmQOMAn9cOq9tLmQgqgBU0MUby6Ek3XzYZKaEqm7Jlj1ahd8mmN8Oc3KRazC-2FblANam8bPbTLn-2FjWWWLUSgmA1wodSMbe-2BDntVINQ-3D-3D) The report, received 1 to 2 hours after the Friday close, can be signed up for on the SRNE web site and includes daily numbers for the week...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_102_0</DOCNO>
            	<TEXT>When intolerance becomes the norm, intelligent communication comes to a halt.... and knowledge is stifled.....</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_104_0</DOCNO>
            	<TEXT>At my age what I want in life is to keep and possibly improve health.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_104_1</DOCNO>
            	<TEXT>Clint Eastwood is now 92 years old.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_104_2</DOCNO>
            	<TEXT>When he was 88, 4 years ago, Toby Keith wrote a song and performed it for his friend Clint.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_104_3</DOCNO>
            	<TEXT>It hits the point I want to make.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_104_4</DOCNO>
            	<TEXT>It's called "Don't let the old man in" Search and listen/watch it, you will enjoy it as much as I.........</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_105_0</DOCNO>
            	<TEXT>I like this one paragraph tremendously!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_105_1</DOCNO>
            	<TEXT> The new drug review timeline has been shortened significantly.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_105_2</DOCNO>
            	<TEXT>The clinical trial IND timeline, which had taken one to two years prior to 2015, has been reduced to about three months (60-working-day silent approval).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_105_3</DOCNO>
            	<TEXT>Wake up FDA!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_106_0</DOCNO>
            	<TEXT>Interesting explanation........</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_106_1</DOCNO>
            	<TEXT>Yes, this has nothing to do with SRNE, but enjoy and give it some thought...... *The population of Earth is around 7.8 Billion.* *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_106_2</DOCNO>
            	<TEXT>For most people, it is a large figure* *However, if you condensed 7.8 billion into 100 persons, and then into various percentage statistics* *the resulting analysis is relatively much easier to comprehend.* *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_106_3</DOCNO>
            	<TEXT>Out of 100:* *11 are in Europe* *5 are in North America* *9 are in South America* *15 are in Africa* *60 are in Asia* *49 live in the countryside* *51 live in cities* *12 speak Chinese* *5 speak Spanish* *5 speak English* *3 speak Arabic* *3 speak Hindi* *3 speak Bengali* *3 speak Portuguese* *2 speak Russian* *2 speak Japanese* *62 speak their own language.* *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_106_4</DOCNO>
            	<TEXT>77 have their own dwellings.* *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_106_5</DOCNO>
            	<TEXT>23 have no place to live.* *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_106_6</DOCNO>
            	<TEXT>21 are over-nourished.* *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_106_7</DOCNO>
            	<TEXT>63 can eat full.* *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_106_8</DOCNO>
            	<TEXT>15 are under-nourished* *1 ate the last meal, but did not make it to the next meal.* *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_106_9</DOCNO>
            	<TEXT>The daily cost of living for 48 is less than 2 USD (US Dollars).* *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_106_10</DOCNO>
            	<TEXT>87 have clean drinking water* *13 either lack clean drinking water or have a water source that is polluted.* *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_106_11</DOCNO>
            	<TEXT>75 have mobile phones* *25 do not.* *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_106_12</DOCNO>
            	<TEXT>30 have internet access* *70 do not have the availabilty to go online* *7 received university education* *93 did not attend college.* *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_106_13</DOCNO>
            	<TEXT>83 can read* *17 are illiterate.* *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_106_14</DOCNO>
            	<TEXT>33 are Christians* *22 are Muslims* *14 are Hindus* *7 are Buddhists* *12 are other religions* *12 have no religious beliefs.* *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_106_15</DOCNO>
            	<TEXT>26 live less than 14 years* *66 died between 15 - 64 years of age* *8 are over 65 years old.* *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_106_16</DOCNO>
            	<TEXT>If you have your own home,* *Eat full meals  amp; drink clean water,* *Have a mobile phone,* *Can surf the internet, and* *have gone to college,* *You are in the miniscule privileged lot.* *(</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_106_17</DOCNO>
            	<TEXT>in the less than 7% category)* *Amongst 100 persons in the world, only 8 live or exceed the age of 65.* *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_106_18</DOCNO>
            	<TEXT>If you are over 65 years old,* *be content  amp; grateful.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_106_19</DOCNO>
            	<TEXT>Cherish life, grasp the moment.* *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_106_20</DOCNO>
            	<TEXT>If you did not leave this world before the age of 64 like the 92 persons who have gone before you,* *you are already the blessed amongst mankind.* *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_106_21</DOCNO>
            	<TEXT>Take good care of your own health.* *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_106_22</DOCNO>
            	<TEXT>Cherish every remaining moment.*</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_107_0</DOCNO>
            	<TEXT>And don't forget with well stocked waters, it's only a matter of time to land a good catch and the big one!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_108_0</DOCNO>
            	<TEXT>Buyout...Big Pharma acquiring...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_109_0</DOCNO>
            	<TEXT>Best morning read in a long time.....AMEN.........</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_110_0</DOCNO>
            	<TEXT>The snowball is getting bigger, more powerful and the 'shorts' are directly in the path of something they can no longer stop!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_111_0</DOCNO>
            	<TEXT>Without any doubt!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_112_0</DOCNO>
            	<TEXT>Would this qualify as day 1?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_113_0</DOCNO>
            	<TEXT>Great post, thank you.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_113_1</DOCNO>
            	<TEXT>I for one have been increasing the size of my stocking in anticipation of it being filled!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_114_0</DOCNO>
            	<TEXT>No-Substance; I believe you have expressed the thoughts and frustrations of many longs who are holding their shares knowing the end result will be extremely rewarding.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_114_1</DOCNO>
            	<TEXT>During this waiting period of growth all, I imagine, would like to hear more communication from management.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_114_2</DOCNO>
            	<TEXT>Dr Ji is a master in what he does best and it certainly would help if a PR pro was hired or promoted to that position....</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_115_0</DOCNO>
            	<TEXT>Nice find, thanks..Explains why we need the FDA investigated and the system of approving drugs and granting EUAs scrutinized.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_115_1</DOCNO>
            	<TEXT>One aspect which should end immediately is the process of submission by biotech and pharma companies.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_115_2</DOCNO>
            	<TEXT>When big pharmas pay to have their trials looked at by the FDA, which finances the FDA, then they will always get special treatment leaving small biotechs on the back burner.. This is why Sorrento is seeking approvals and EUAs throughout the world while waiting for the FDA to act...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_116_0</DOCNO>
            	<TEXT>I agree that it would pack a punch if we would get a Friday release of news, but that's not likely to happen.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_116_1</DOCNO>
            	<TEXT>The last Friday release was on June 11, 2021. "</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_116_2</DOCNO>
            	<TEXT>Sorrento Receives Authorization From the UK Regulatory Agency to Conduct a Phase 2 Clinical Trial for COVI-DROPS in an Outpatient Setting".</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_117_0</DOCNO>
            	<TEXT>10-Q Released</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_117_1</DOCNO>
            	<TEXT>Sorrento financials released in Form 10Q. View it on the Website.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_117_2</DOCNO>
            	<TEXT>I am still going over it.....</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_118_0</DOCNO>
            	<TEXT>Liquidity and Going Concern The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_118_1</DOCNO>
            	<TEXT>The Company has recurring losses from operations, recurring negative cash flows from operations and substantial cumulative net losses to date and anticipates that it will continue to do so for the foreseeable future as it continues to identify and invest in advancing product candidates, as well as expanding corporate infrastructure.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_118_2</DOCNO>
            	<TEXT>The Company has plans in place to obtain sufficient additional fundraising to fulfill its operating, debt servicing and capital requirements for the next 12 months.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_118_3</DOCNO>
            	<TEXT>The Companys plans include continuing to fund its operating losses and capital funding needs through public or private equity or debt financings, strategic collaborations, licensing arrangements, asset sales, government grants or other arrangements.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_118_4</DOCNO>
            	<TEXT>Although management believes such plans, if executed, should provide the Company sufficient financing to meet its needs, successful completion of such plans is dependent on factors outside of the Companys control.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_118_5</DOCNO>
            	<TEXT>As such, management cannot conclude that such plans will be effectively implemented within one year after the date that the financial statements are issued.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_118_6</DOCNO>
            	<TEXT>As a result, management has concluded that the aforementioned conditions, among others, raise substantial doubt about the Companys ability to continue as a going concern for one year after the date the financial statements are issued.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_118_7</DOCNO>
            	<TEXT>If the Company is unable to raise additional capital in sufficient amounts or on terms acceptable, the Company may have to significantly delay, scale back or discontinue the development or commercialization of one or more of its product candidates.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_118_8</DOCNO>
            	<TEXT>The Company may also seek collaborators for one or more of its current or future product candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_118_9</DOCNO>
            	<TEXT>Furthermore, the spread of COVID-19, which has caused a broad impact globally, may materially affect the Company economically.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_118_10</DOCNO>
            	<TEXT>While the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, a widespread pandemic could result in significant disruption of global financial markets, reducing the Companys ability to access capital, which could, in the future, negatively affect its liquidity.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_118_11</DOCNO>
            	<TEXT>The consolidated financial statements do not reflect any adjustments that might be necessary if the Company is unable to continue as a going concern.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_118_12</DOCNO>
            	<TEXT>If the Company raises additional funds by issuing equity securities, substantial dilution to existing stockholders would result.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_118_13</DOCNO>
            	<TEXT>If the Company raises additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict the Companys ability to operate its business.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_118_14</DOCNO>
            	<TEXT>Disclosures are fairly normal in full disclosure to shareholders....</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_119_0</DOCNO>
            	<TEXT>Surprised me also, I'm confident next quarter will turn this around.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_120_0</DOCNO>
            	<TEXT>Yes, normal disclosures and concerns...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_121_0</DOCNO>
            	<TEXT>Weekly report from Sorrento</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_121_1</DOCNO>
            	<TEXT>Sorrento Therapeutics added the following items during the week of **November 1, 2021** #### All News Releases [Sorrentos License Partner, Lees Pharmaceutical Announces NDA Filing Acceptance by NMPA for Anti-PD-L1 Antibody Socazolimab for Treatment of Recurrent or Metastatic Cervical Cancer](http://url9490.notification.gcs-web.com/ls/click?upn=Vk1mmV-2F2BYXMSdrc2O0yE3dIdyJ36Qf-2BrVD74w8Wyr-2BJYIQfsy88dcRAv-2F2EJ6vIET4GgcfBMIk9tSVDdAPZV9Bcyz5l0t5Y1tg68Epn-2BsKM51WrCRwZbVIWKe7i-2F83s5VPMRhcB0WIrSCwQOw6r2Nusgb6KA4CPeEvnvJykgeXzhVdVkSv7uic9H3Dlje37xMOjcA3rINT7rJlsydt3vA-3D-3DvgBb_DKMwEV5rE6ItJiX8ruKGZFPAKW3-2FBj8orHheDZHS-2F07idJuKH6yPcaZWWj7xUPGGX-2BXxIQ2rVl-2BF47T30pYRscKYxIkJ3y5X-2BSTaQJ89lt1oH5xBflVtwsBcCpkdNC7ZzoswH-2F9pX-2Fw8AOjS0tXCbQ79gd9n2TrJGhS98gT0K9BhtMu4GXzgdUxTglmqwaItQPh-2BQXth4t2Vob-2B-2Fyn6Aoa19It6MNaE1KRgBFCoXDamTPIas6l-2Fg4jGAOkjTmaaY1m3h-2BoRU8iIRsW-2FEA7zwlg-3D-3D) [Sorrento Receives Brazilian Health Regulatory Agency (ANVISA) Approval for COVISTIX (COVID-19 Virus Antigen Detection Test) for Brazil](http://url9490.notification.gcs-web.com/ls/click?upn=Vk1mmV-2F2BYXMSdrc2O0yE3dIdyJ36Qf-2BrVD74w8Wyr-2BJYIQfsy88dcRAv-2F2EJ6vIET4GgcfBMIk9tSVDdAPZV9Bcyz5l0t5Y1tg68Epn-2BsIniftGSna5j50r4rl488ovpTdYn4WTD8g9nzWI7iqki8kOxzrV9FDv6zzX-2FGx6nhYKuynbMMQ-2FD-2FCzwugAi2-2FIleCdFx8lmvbo7qsuKJqGqg-3D-3D4_rZ_DKMwEV5rE6ItJiX8ruKGZFPAKW3-2FBj8orHheDZHS-2F07idJuKH6yPcaZWWj7xUPGGX-2BXxIQ2rVl-2BF47T30pYRscKYxIkJ3y5X-2BSTaQJ89lt1oH5xBflVtwsBcCpkdNC7ZnDW3KqggAPz7lZOx6irJnLlYs-2B81B3nDqLFq5zrQ-2B2-2F5yi1YzGpBmhz27u-2FjB7EYdW2YhSwCAEoAHWg4pZsHpaXxdekPqod9nQdlaSHGLaS0uI2yaN8QeDU-2BveXguNOTIRq9Sg40dGJ1oI01obiyXg-3D-3D) The 10-Q was also released today showing the financials.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_121_2</DOCNO>
            	<TEXT>In my opinion the next quarter will be the turnaround quarter we have been waiting for.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_121_3</DOCNO>
            	<TEXT>It should show significant progress and revenues from COVI-Stix, additional acceptance from many countries in need or Sorrento's testing and advancement of a number of trials... and who knows, maybe the FDA will be shamed enough to respond favorably..</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_122_0</DOCNO>
            	<TEXT>The 10-Q did not contain anything to spark any solid interest, nor did it contain COVI-Stix revenue as many were expecting.. we are one quarter away in my opinion...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_123_0</DOCNO>
            	<TEXT>Agree 100%... I will be making my bets tonight for tomorrows games, always ready for football!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_124_0</DOCNO>
            	<TEXT>A amp;M. One of the toughest places to play.!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_124_1</DOCNO>
            	<TEXT>Home of the 12th man.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_125_0</DOCNO>
            	<TEXT>Results released Friday are not what we wanted, but are what we expected.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_125_1</DOCNO>
            	<TEXT>There are so much in the works that no 'long' should have any concerns or worries.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_125_2</DOCNO>
            	<TEXT>Yes, we most likely take a hit on Monday, but I , for one, did not invest in this company for Monday's action or next week or next month.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_125_3</DOCNO>
            	<TEXT>I am in for the long term, which I am quite satisfied with the progress to date and certainly with the above list............. Revenues will be coming.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_127_0</DOCNO>
            	<TEXT>I am not a finance guy myself but do agree with your concerns within the 10Q. Having said that, with so much on the verge of coming to fruition I see no reason to be stressed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_127_1</DOCNO>
            	<TEXT>With the latest hiring, expansion, and the number of counties coming on board with COVI-Stix among other events taking place or about to, I know my investment is solid.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_127_2</DOCNO>
            	<TEXT>I also believe Dr Ji has that hat full of rabbits!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_128_0</DOCNO>
            	<TEXT>Exciting times ahead for Sorrento and it's investors...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_129_0</DOCNO>
            	<TEXT>Looks to me that Sofusa (S-LDS) is progressing nicely.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_129_1</DOCNO>
            	<TEXT>Bioserv tooling up for the eventual production and the FDA conducting inspections?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_129_2</DOCNO>
            	<TEXT>The State of California favoring both Bioserv and Sorrento, hence the recent tax break for Sorrento granted by the State......as a good friend says, the best is yet to come!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_130_0</DOCNO>
            	<TEXT>COVI-Stix is certainly the immediate logical thought....</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_131_0</DOCNO>
            	<TEXT>Nice video of an easy-to-understand formulation of the science behind it.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_131_1</DOCNO>
            	<TEXT>The future is getting more exciting weekly if not daily...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_132_0</DOCNO>
            	<TEXT>Gotta love progress.....</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_133_0</DOCNO>
            	<TEXT>Nice to have some "Brothers" with eyes on the ground!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_133_1</DOCNO>
            	<TEXT>Looking forward to those pics..</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_134_0</DOCNO>
            	<TEXT>The need for COVI-Stix is worldwide and with production ramping up in anticipation of orders coming in will translate to the long-awaited revenue which is what is needed to send the share price back up into double digits and send the 'shorts' packing....</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_135_0</DOCNO>
            	<TEXT>The scenario you have laid out would be a great way to end the year........ One can only hope and wait.........</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_136_0</DOCNO>
            	<TEXT>More evidence of the corruption in the FDA.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_136_1</DOCNO>
            	<TEXT>Thanks for posting the letter....</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_137_0</DOCNO>
            	<TEXT>MikeD44 is one of the most informative posters and in my top 5 Which I look forward to reading whenever they choose to share their thoughts..</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_138_0</DOCNO>
            	<TEXT>Well said by a true American!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_138_1</DOCNO>
            	<TEXT>Prejudice and racism are destroying our nation.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_138_2</DOCNO>
            	<TEXT>The political policies of "Wokeness" and the racist CRT movement are dividing the country to what end I don't know....</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_139_0</DOCNO>
            	<TEXT>Sorrento's Weekly Summary</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_139_1</DOCNO>
            	<TEXT>Sorrento Therapeutics added the following items during the week of **November 8, 2021** #### All News Releases [Sorrento Awarded California Competes Tax Credit](http://url9490.notification.gcs-web.com/ls/click?upn=Vk1mmV-2F2BYXMSdrc2O0yE3dIdyJ36Qf-2BrVD74w8Wyr-2BJYIQfsy88dcRAv-2F2EJ6vIET4GgcfBMIk9tSVDdAPZV9Bcyz5l0t5Y1tg68Epn-2BsJxt2Qa7HN8Nuu46WqV7VpkCXJ6-2Fg83j57Up0dYuJ6F0Aa3dUcsaRr6-2BQVS-2FthOHqNGDkxN8QGKuGWh4iRGVLYQdHGP_DKMwEV5rE6ItJiX8ruKGZFPAKW3-2FBj8orHheDZHS-2F07idJuKH6yPcaZWWj7xUPGGPP8asHRAFs37mBAnmLbLgsYcrqgUApppTa4GwsWtC-2BZ-2Baz5E9NLjRNfujj7HIO3TD6fEKXg9lXevqWDPspO0EGUGdiMTp0uELlJOGWMHQoieiVN26h5XYwAuKJN4dMdVP13wNkrYg3jhP8SGhCHJ47i-2FkBe77PLue5u-2BhIxSs59Bmf3utxAR5TTFH-2B7RiFjYWv30FYNDzT8BEbak-2Bha-2BXw-3D-3D) [Sorrento Announces Publication of Significant Positive Pivotal Trial Results of Abivertinib for the Treatment of Non-Small Cell Lung Cancer (NSCLC) in the Peer-Reviewed Journal Clinical Cancer Research](http://url9490.notification.gcs-web.com/ls/click?upn=Vk1mmV-2F2BYXMSdrc2O0yE3dIdyJ36Qf-2BrVD74w8Wyr-2BJYIQfsy88dcRAv-2F2EJ6vIET4GgcfBMIk9tSVDdAPZV9Bcyz5l0t5Y1tg68Epn-2BsJxt2Qa7HN8Nuu46WqV7VpkPNOt86EKXmKaE4EyCmH0pyzQUkFiNmSD6XYwIgDMrFVPG1Eetm-2FCnKDu31QzutMmpWaHQdJHD4WOCPB-2BRzBNXg-3D-3DHUw6_DKMwEV5rE6ItJiX8ruKGZFPAKW3-2FBj8orHheDZHS-2F07idJuKH6yPcaZWWj7xUPGGPP8asHRAFs37mBAnmLbLgsYcrqgUApppTa4GwsWtC-2BZ-2Baz5E9NLjRNfujj7HIO3T70M8LirzNuhgMWGy3nZVuxTjNanUzoFVWUujawp0X5wh0QlBRq-2FiaxAVDOPLmVX-2B9VuuY0P0nogPS267Q9Cv3nhy7L2of5tBZkgx9kWryisaM92M0k9lReT-2FJZhTQTMy-2FFtPmCnV4-2BpmCbtlpB1LRA-3D-3D) [Sorrento Therapeutics Mexico to Partner with the World Boxing Council for the Screening of COVID-19 of all Convention Attendees with COVI-STIX at the 59th World Boxing Council Convention in Mexico City](http://url9490.notification.gcs-web.com/ls/click?upn=Vk1mmV-2F2BYXMSdrc2O0yE3dIdyJ36Qf-2BrVD74w8Wyr-2BJYIQfsy88dcRAv-2F2EJ6vIET4GgcfBMIk9tSVDdAPZV9Bcyz5l0t5Y1tg68Epn-2BsIvori-2BwbwK3CIoqyUzrrYJV3Ay-2BFRVlza9yJNGk5nYZMSG6j3ZetJFtK405wnhuzEAZSkMFhDefIAY8v6eqTw0eB_i_DKMwEV5rE6ItJiX8ruKGZFPAKW3-2FBj8orHheDZHS-2F07idJuKH6yPcaZWWj7xUPGGPP8asHRAFs37mBAnmLbLgsYcrqgUApppTa4GwsWtC-2BZ-2Baz5E9NLjRNfujj7HIO3TmHUPUssQ-2BbqBuYzEWgno6W6wbmXiZp4mbqyD4nHCuxh9YRM311NX9RYpSJQFHEN6s7msodKk8W6RUve09jurnUckvJ8VzJB56YzHaIZsBEHebhnUHM2XLzVPM-2BxnZ8CRDNFU4m36UPnicF-2Ft7zVnGg-3D-3D)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_140_0</DOCNO>
            	<TEXT>Great post as always, thanks Robert.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_140_1</DOCNO>
            	<TEXT>Taking a break to check my messages.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_140_2</DOCNO>
            	<TEXT>Total havoc here with wedding at 3pm.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_140_3</DOCNO>
            	<TEXT>Guests arriving too damn early!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_140_4</DOCNO>
            	<TEXT>Gotta hide my top shelf bourbon or I will strangle someone who pours it into a cola!!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_141_0</DOCNO>
            	<TEXT>Please add Tennessee to your list.... I would suggest the first party planned for when we top the $50 pps mark in 2022......</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_142_0</DOCNO>
            	<TEXT>Sorrento's Cancer pipeline is very impressive with Abivertinib destined to become a future 'wonder drug' applicable to many needs in the world of health.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_143_0</DOCNO>
            	<TEXT>One can only imagine the future revenue if the #1 sport, football (Soccer), in the world adopted COVI-Stix for testing all attendees at all events worldwide.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_143_1</DOCNO>
            	<TEXT>Let's start with the World Cup coming up beginning next week..</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_144_0</DOCNO>
            	<TEXT>Not a lot of info provided, but the no vote was a success for shareholders.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_144_1</DOCNO>
            	<TEXT>Sends a message of frustration and anxiety from those who own the company.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_144_2</DOCNO>
            	<TEXT>The current share price in light of 'shorting' needs to be addressed by management!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_145_0</DOCNO>
            	<TEXT>The headline says 5 million and in the write-up we see 'up to 5 million'.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_145_1</DOCNO>
            	<TEXT>Certainly contradictory and in need of clarity.... But, good news in itself...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_146_0</DOCNO>
            	<TEXT>I have been been hospitalized for the past few days due to a serious infection following surgery 1 week ago.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_146_1</DOCNO>
            	<TEXT>I am now home and recovering nicely.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_146_2</DOCNO>
            	<TEXT>looking forward to a great Thanksgiving tomorrow and wish all my Sorrento family the same.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_147_0</DOCNO>
            	<TEXT>Excellent find.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_147_1</DOCNO>
            	<TEXT>Very interesting read on an influential Admiral with contacts in the right places.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_147_2</DOCNO>
            	<TEXT>Sorrento's network of influential people is far reaching... It's only a matter of time....</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_148_0</DOCNO>
            	<TEXT>Excellent find from BANDOFBROTHERSOFSRNE.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_148_1</DOCNO>
            	<TEXT>Many other great informative posts available daily over there.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_148_2</DOCNO>
            	<TEXT>If you are not a member please join and enjoy.....</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_149_0</DOCNO>
            	<TEXT>Thank you and many others for your kind wishes.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_149_1</DOCNO>
            	<TEXT>I'm getting better daily, thank you.....</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_150_0</DOCNO>
            	<TEXT>As in building a successful business, completing a 1000 piece jig-saw puzzle requires putting together the pieces in the correct location at the right time.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_150_1</DOCNO>
            	<TEXT>In doing so a successful outcome of all the pieces falling together will result in the creation of a beautiful thing!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_150_2</DOCNO>
            	<TEXT>This approach takes time, but is both satisfying and worth it in the end.....</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_151_0</DOCNO>
            	<TEXT>My favorite Bronson films are; 'Once upon a time in the West' and 'The Great Escape'.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_152_0</DOCNO>
            	<TEXT>Is the FDA really doing all it can?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_152_1</DOCNO>
            	<TEXT># [Coronavirus (COVID-19) Update: FDA Actively Working to Investigate, Address Potential Impacts of Omicron Variant; Urges Vaccination and Boosters](https://lnks.gd/l/eyJhbGciOiJIUzI1NiJ9.eyJidWxsZXRpbl9saW5rX2lkIjoxMDEsInVyaSI6ImJwMjpjbGljayIsImJ1bGxldGluX2lkIjoiMjAyMTExMzAuNDk1NDAxOTEiLCJ1cmwiOiJodHRwczovL3d3dy5mZGEuZ292L25ld3MtZXZlbnRzL3ByZXNzLWFubm91bmNlbWVudHMvY29yb25hdmlydXMtY292aWQtMTktdXBkYXRlLWZkYS1hY3RpdmVseS13b3JraW5nLWludmVzdGlnYXRlLWFkZHJlc3MtcG90ZW50aWFsLWltcGFjdHMtb21pY3Jvbj91dG1fbWVkaXVtPWVtYWlsJnV0bV9zb3VyY2U9Z292ZGVsaXZlcnkifQ.EkKZoM8bk4p-4xPSlLWibLkljRR7UYyBl-_hvuxuPoQ/s/1419462572/br/121940273383-l) ### The following is attributed to Acting FDA Commissioner Janet Woodcock, M.D. As we have with previous emerging COVID-19 variants, the U.S. Food and Drug Administration is actively working with our federal partners, international regulators and medical product companies to quickly address any potential impacts of the new omicron variant on the tools to fight the pandemic.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_152_2</DOCNO>
            	<TEXT>The agency is working as quickly as possible to evaluate the potential impact of this variant on the currently available diagnostics, therapeutics and vaccines.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_152_3</DOCNO>
            	<TEXT>We are closely monitoring the situation and are committed to communicating with the public as we learn more.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_152_4</DOCNO>
            	<TEXT>Historically, the work to obtain the genetic information and patient samples for variants and then perform the testing needed to evaluate their impact takes time.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_152_5</DOCNO>
            	<TEXT>However, we expect the vast majority of this work to be completed in the coming weeks.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_152_6</DOCNO>
            	<TEXT>The FDA has been actively monitoring for the possible emergence of SARS-CoV-2 variants since early in the pandemic and has worked with medical product developers when a new variant (or mutation) emerges that could impact product performance. *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_152_7</DOCNO>
            	<TEXT>With [industry guidance laid out in February](https://lnks.gd/l/eyJhbGciOiJIUzI1NiJ9.eyJidWxsZXRpbl9saW5rX2lkIjoxMDIsInVyaSI6ImJwMjpjbGljayIsImJ1bGxldGluX2lkIjoiMjAyMTExMzAuNDk1NDAxOTEiLCJ1cmwiOiJodHRwczovL3d3dy5mZGEuZ292L25ld3MtZXZlbnRzL3ByZXNzLWFubm91bmNlbWVudHMvY29yb25hdmlydXMtY292aWQtMTktdXBkYXRlLWZkYS1pc3N1ZXMtcG9saWNpZXMtZ3VpZGUtbWVkaWNhbC1wcm9kdWN0LWRldmVsb3BlcnMtYWRkcmVzc2luZy12aXJ1cz91dG1fbWVkaXVtPWVtYWlsJnV0bV9zb3VyY2U9Z292ZGVsaXZlcnkifQ.R_e3qDYM8besK94LB7aRxV9zJO00koQELyuNX_3RIVY/s/1419462572/br/121940273383-l) and contingency plans already in place, we are well-positioned and committed to working with companies to evaluate and expeditiously address the potential impact of emerging and future viral mutations on COVID-19 tests, therapeutics and vaccines. *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_152_8</DOCNO>
            	<TEXT>Weve taken a number of steps to adapt to emerging variants thus far in the pandemic, such as requiring companies to actively monitor for and evaluate the impact of variants on their products as a condition of authorization, and quickly taking appropriate action. *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_152_9</DOCNO>
            	<TEXT>The agency has previously[ limited the scope of use of certain monoclonal antibodies](https://lnks.gd/l/eyJhbGciOiJIUzI1NiJ9.eyJidWxsZXRpbl9saW5rX2lkIjoxMDMsInVyaSI6ImJwMjpjbGljayIsImJ1bGxldGluX2lkIjoiMjAyMTExMzAuNDk1NDAxOTEiLCJ1cmwiOiJodHRwczovL3d3dy5mZGEuZ292L21lZGlhLzE1MTcxOS9kb3dubG9hZD91dG1fbWVkaXVtPWVtYWlsJnV0bV9zb3VyY2U9Z292ZGVsaXZlcnkifQ.gRD4gLN402TA6pM1U6pXeaP5reZQNP9Az6OkEqJW6hE/s/1419462572/br/121940273383-l) depending on variants circulating in certain areas, updated [fact sheets for health care providers](https://lnks.gd/l/eyJhbGciOiJIUzI1NiJ9.eyJidWxsZXRpbl9saW5rX2lkIjoxMDQsInVyaSI6ImJwMjpjbGljayIsImJ1bGxldGluX2lkIjoiMjAyMTExMzAuNDk1NDAxOTEiLCJ1cmwiOiJodHRwczovL3d3dy5mZGEuZ292L21lZGlhLzE0OTUzNC9kb3dubG9hZD91dG1fbWVkaXVtPWVtYWlsJnV0bV9zb3VyY2U9Z292ZGVsaXZlcnkifQ.XCIrKXkkcmPkmwoJHPOYuOBCZdLTdgdHw8qCTEgzti0/s/1419462572/br/121940273383-l) with information about how known variants impact certain therapeutics, and [communicated with the public about tests](https://lnks.gd/l/eyJhbGciOiJIUzI1NiJ9.eyJidWxsZXRpbl9saW5rX2lkIjoxMDUsInVyaSI6ImJwMjpjbGljayIsImJ1bGxldGluX2lkIjoiMjAyMTExMzAuNDk1NDAxOTEiLCJ1cmwiOiJodHRwczovL3d3dy5mZGEuZ292L21lZGljYWwtZGV2aWNlcy9jb3JvbmF2aXJ1cy1jb3ZpZC0xOS1hbmQtbWVkaWNhbC1kZXZpY2VzL3NhcnMtY292LTItdmlyYWwtbXV0YXRpb25zLWltcGFjdC1jb3ZpZC0xOS10ZXN0cz91dG1fbWVkaXVtPWVtYWlsJnV0bV9zb3VyY2U9Z292ZGVsaXZlcnkifQ.EmaGNJXnEdWHMBVBF5_vDH0NO6uKUf1Xq_v9-dw0_co/s/1419462572/br/121940273383-l) affected by viral mutations. *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_152_10</DOCNO>
            	<TEXT>We anticipate having more information from the ongoing evaluation regarding if and how well the current vaccines work against this variant in the next few weeks.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_152_11</DOCNO>
            	<TEXT>If a modification to the current vaccines is needed, the FDA and companies will work together to develop and test such a modification quickly. *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_152_12</DOCNO>
            	<TEXT>On preliminary review, we believe high-volume polymerase chain reaction (PCR) and antigen (rapid) tests widely used in the U.S. show low likelihood of being impacted and continue to work.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_152_13</DOCNO>
            	<TEXT>However, the FDA will continue to closely review and adjust course as needed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_152_14</DOCNO>
            	<TEXT>The FDA is committed to continuing to use every tool in our toolbox to fight this pandemic, including pivoting as the virus adapts, to arm ourselves with the best available diagnostics, and life-saving therapeutics and vaccines to fight this virus.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_153_0</DOCNO>
            	<TEXT>Trivers is a 1 post ID.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_153_1</DOCNO>
            	<TEXT>Without a doubt it is deepbluesea with just another ID....</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_154_0</DOCNO>
            	<TEXT>Hopefully the tease doesn't backfire and Dr Ji ends up entertaining a buy-out offer!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_154_1</DOCNO>
            	<TEXT>A partnership would be acceptable as long as we retain the vast majority interest....</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_155_0</DOCNO>
            	<TEXT> gt;That would certainly create interest and bring on additional investors from the exposure..a win-win....</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_156_0</DOCNO>
            	<TEXT>I can only imagine, a future reality, if 60 out of 60 near death patients walked out within days of treatment!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_156_1</DOCNO>
            	<TEXT>The market interest would skyrocket along with the stock price and the shorts would be teetering on high rise ledges!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_157_0</DOCNO>
            	<TEXT>If you are not excited about the future of this company, please check your pulse!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_157_1</DOCNO>
            	<TEXT>Weekly, if not daily, Sorrento is adding new weapons to it's arsenal...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_158_0</DOCNO>
            	<TEXT>Many SRNE investors are frustrated with the current price per share and the ever present short manipulation but there is no reason to use unacceptable language to express that frustration.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_159_0</DOCNO>
            	<TEXT>Your 4800 shares at the future minimum price of $50 is about a quarter million.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_159_1</DOCNO>
            	<TEXT>Not a pauper's net worth at all!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_160_0</DOCNO>
            	<TEXT>LONGS, we seem to have a number of yahoo shorts coming over to trash and try to get your shares.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_160_1</DOCNO>
            	<TEXT>Just block them as I am doing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_160_2</DOCNO>
            	<TEXT>This only shows their desperation.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_160_3</DOCNO>
            	<TEXT>Don't let them get to you, stay strong and enjoy your weekend...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_161_0</DOCNO>
            	<TEXT>After market action</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_161_1</DOCNO>
            	<TEXT>**Supplement No.1 dated December3, 2021** **To Prospectus Supplement dated December4, 2020** **(to Prospectus dated March20, 2020)** **$450,000,000** **Common Stock** This supplement, or this Supplement, supplements certain information contained in the prospectus supplement dated December4, 2020, or the Prospectus Supplement, relating to the offer and sale of shares of our common stock having an aggregate offering price of up to $450,000,000 from time to time to or through A.G.P./Alliance Global Partners, or A.G.P., acting as sales agent or principal, in sales deemed to be at the market offerings as defined in Rule415 promulgated under the Securities Act of 1933, as amended, or the Securities Act.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_161_2</DOCNO>
            	<TEXT>This Supplement should be read in conjunction with the Prospectus Supplement and the Prospectus dated March20, 2020.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_161_3</DOCNO>
            	<TEXT>Capitalized terms used and not defined herein shall have the meanings ascribed to such terms in the Prospectus Supplement.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_161_4</DOCNO>
            	<TEXT>This Supplement amends only those sections of the prospectus supplement listed in this Supplement; all other sections of Prospectus Supplement remain as is.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_161_5</DOCNO>
            	<TEXT>This Supplement is being filed to reflect the amendment and restatement on December3, 2021, of that certain sales agreement dated April27, 2020, as amended on December4, 2020, between us and A.G.P., to include Cantor Fitzgerald amp; Co., B. Riley Securities,Inc. and H.C. Wainwright amp; Co., LLC as additional sales agents in sales deemed to be at the market offerings as defined in Rule415 promulgated under the Securities Act.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_161_6</DOCNO>
            	<TEXT>Accordingly, each reference to the terms sales agent and A.G.P. in the Prospectus Supplement are hereby amended to refer to sales agents and include Cantor Fitzgerald amp; Co., B. Riley Securities,Inc. and H.C. Wainwright amp; Co., LLC and each reference to the term sales agreement in the Prospectus Supplement is hereby amended to refer to the amended and restated sales agreement.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_161_7</DOCNO>
            	<TEXT>As of December1, 2021, we have sold an aggregate of 52,076,932 shares of our common stock for gross proceeds of approximately $415.9 million under the sales agreement pursuant to the Prospectus Supplement and a prior prospectus supplement relating to the sales agreement, dated April27, 2020.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_161_8</DOCNO>
            	<TEXT>As of December3, 2021, shares of common stock having an aggregate offering price of $284.1 million are available for sale under the Prospectus Supplement and this Supplement.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_161_9</DOCNO>
            	<TEXT>Our common stock is currently listed on the Nasdaq Capital Market under the symbol SRNE.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_161_10</DOCNO>
            	<TEXT>On December2, 2021, the last reported sale price of our common stock was $5.51. ***</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_161_11</DOCNO>
            	<TEXT>Investing in our common stock involves a high degree of risk.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_161_12</DOCNO>
            	<TEXT>You should review carefully the risks and uncertainties described under the heading Risk Factors on pageS-6 of the Prospectus Supplement, and under similar headings in the documents that are incorporated by reference into the Prospectus Supplement and the accompanying Prospectus.***</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_162_0</DOCNO>
            	<TEXT>You are absolutely correct....</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_163_0</DOCNO>
            	<TEXT>Weekly summary</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_163_1</DOCNO>
            	<TEXT>Sorrento Therapeutics added the following items during the week of **November 29, 2021** #### All SEC Filings [8-K](http://url9490.notification.gcs-web.com/ls/click?upn=Vk1mmV-2F2BYXMSdrc2O0yE3dIdyJ36Qf-2BrVD74w8Wyr-2BJYIQfsy88dcRAv-2F2EJ6vI6UuxqoBjtRSFeIqj2j-2FNe4sgMxDuXiRPbzMgtrXATCV83xTCIWHj-2BowXifMFmPvmCNMIGB7rrKNCbQ04jz3hgg-3D-3D36Sh_DKMwEV5rE6ItJiX8ruKGZFPAKW3-2FBj8orHheDZHS-2F07idJuKH6yPcaZWWj7xUPGGkcZInIGD-2FvBbRBD5f6twDrhO-2Fo4qNuNTIGHHupv-2FvJn3GdwfmSg6V6rTkxKgpMAWlpDe7nsKqLqwWJcCF-2B2HMbo-2BoBotVVaO5OJRjpRBPJTMSByMOPuCaBsYFTqqHWlSSbmUMBrjHnGHZ-2BPZqqKmp6bG4ImAg5OrtTjLz9VcnMC3mAA7-2BCe3fCTl-2F4JbiciM6goljFIJGAQPquIBkneQBw-3D-3D) [8-K](http://url9490.notification.gcs-web.com/ls/click?upn=Vk1mmV-2F2BYXMSdrc2O0yE3dIdyJ36Qf-2BrVD74w8Wyr-2BJYIQfsy88dcRAv-2F2EJ6vI6UuxqoBjtRSFeIqj2j-2FNe4sgMxDuXiRPbzMgtrXATCVOCPUazXSoueTBF94pFyoX-2F-2B65ElNfPPpj77fjZoI9MA-3D-3D7iLD_DKMwEV5rE6ItJiX8ruKGZFPAKW3-2FBj8orHheDZHS-2F07idJuKH6yPcaZWWj7xUPGGkcZInIGD-2FvBbRBD5f6twDrhO-2Fo4qNuNTIGHHupv-2FvJn3GdwfmSg6V6rTkxKgpMAW-2BRVj6AK4OegU3RyhhGcq4JOgSKgCmUy0ShsJydt6Zj84dGihipkNJZazDYMMOsNqYgAt-2F83Xxu0kH-2Fhs-2FB3nUucoyJLQDuwxtFbhGgkz54uhIBg8mKS-2BetD4Os9Im0ii6C2NKyiO3NODzc9TYZkuZw-3D-3D) [424B5](http://url9490.notification.gcs-web.com/ls/click?upn=Vk1mmV-2F2BYXMSdrc2O0yE3dIdyJ36Qf-2BrVD74w8Wyr-2BJYIQfsy88dcRAv-2F2EJ6vI6UuxqoBjtRSFeIqj2j-2FNewyz-2B-2FdEvdkTOxmryBc1txvLRMKcMTNQHQDxbKK5Wl1RTUryWri93qe7xdF-2BJ7WPiA-3D-3DYFAR_DKMwEV5rE6ItJiX8ruKGZFPAKW3-2FBj8orHheDZHS-2F07idJuKH6yPcaZWWj7xUPGGkcZInIGD-2FvBbRBD5f6twDrhO-2Fo4qNuNTIGHHupv-2FvJn3GdwfmSg6V6rTkxKgpMAWQRTzYy3OG8aVoLVdhBAJ4-2Fu7iCWBEHakgQyaMHSDqta3GFHagXLrAeKAf9yEQ8Z1LQgo-2Bmj8hVlML0dRtiLCc3g3UlQFS4hZrJ2bUkMbnSCmloSRtEL4nmOQX8fM3JA3qxIu6K0vFuu26-2FixAoUV-2BQ-3D-3D) #### All News Releases [Sorrento Publishes an Abivertinib Teaser Entitled Abivertinib a Franchise Oral Therapeutic For Cancer, Covid-19 And Autoimmune Diseases](http://url9490.notification.gcs-web.com/ls/click?upn=Vk1mmV-2F2BYXMSdrc2O0yE3dIdyJ36Qf-2BrVD74w8Wyr-2BJYIQfsy88dcRAv-2F2EJ6vIET4GgcfBMIk9tSVDdAPZV9Bcyz5l0t5Y1tg68Epn-2BsI8t3Ha1nQC3qiwFkiHzp1OaY-2FavjWvLZnWq6daw5qcMxIb7eabuGoz4J5f-2FCu9aWaldB-2Fk-2BlOdpZkJw8GVMt4w-2BWUZbOUqLSD0ESyivF3vGw-3D-3D0P88_DKMwEV5rE6ItJiX8ruKGZFPAKW3-2FBj8orHheDZHS-2F07idJuKH6yPcaZWWj7xUPGGkcZInIGD-2FvBbRBD5f6twDrhO-2Fo4qNuNTIGHHupv-2FvJn3GdwfmSg6V6rTkxKgpMAWJ4CiLotulEquXGxSVGsybmFUG-2B16PG5PftjxMJ28Z3NYFSByqpj4RoCe4MRmBgZ9VEtMmHg2sX4QCu-2FvX1Irrp-2BGZQe2-2Bd5758KEw7MhtIM-2B2xcKTnvgGE80D8rxqlKVmA6f4ZidGJr0Cs3X0Cj0ug-3D-3D) [Dr. Henry Ji to Participate in the CEO Fireside Chat Evercore ISI 4th Annual HealthCONx Conference](http://url9490.notification.gcs-web.com/ls/click?upn=Vk1mmV-2F2BYXMSdrc2O0yE3dIdyJ36Qf-2BrVD74w8Wyr-2BJYIQfsy88dcRAv-2F2EJ6vIET4GgcfBMIk9tSVDdAPZV9Bcyz5l0t5Y1tg68Epn-2BsK6rLyJJDyHJ5uX9riLFZlzwCmupK-2FFyWwNW2CIWntd1pSDNaLgQ7sJGi1-2BDrc7dEYo-2BQaQl20b52ns480Q-2FVAM0SQzJoXmPRBt6M9DcOUe2Q-3D-3DT3N2_DKMwEV5rE6ItJiX8ruKGZFPAKW3-2FBj8orHheDZHS-2F07idJuKH6yPcaZWWj7xUPGGkcZInIGD-2FvBbRBD5f6twDrhO-2Fo4qNuNTIGHHupv-2FvJn3GdwfmSg6V6rTkxKgpMAWXJxU2l8TTqHQm4yXcKfqX11-2FD0-2B0Kmo-2FWozPMzNHvwkxyJY8RB3fMx58OfXeHVEY0jo-2FmTBG9tv2MhLZamW2LfUiYM0-2BoEv5n1Ua-2FaOqpmyPivaDZ2q6FBAyYarUvFfkZup4WteaeB65zwCzzwxlBg-3D-3D) As most know by now $450,000,000 of common stock was issued to be available to the big firms who want to invest in Sorrento's future.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_163_2</DOCNO>
            	<TEXT>This was an agreement from over a year ago.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_163_3</DOCNO>
            	<TEXT>I have no concerns from this action due to a number of reasons as Robert S and I chatted earlier.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_163_4</DOCNO>
            	<TEXT>Funds will now be available to advance programs and most of all, a small bio with a healthy cash position is much more attractive to suitors and potential partners.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_163_5</DOCNO>
            	<TEXT>Not to worry, enjoy your weekend and ignore the shorts who will surely attack on Monday.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_163_6</DOCNO>
            	<TEXT>Stay strong as Sorrento is now financially stronger than it was a few hours ago.....</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_164_0</DOCNO>
            	<TEXT>Reddit vs Yahoo</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_164_1</DOCNO>
            	<TEXT>At the time of this post we have 47 on line and Yahoo has only 8!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_164_2</DOCNO>
            	<TEXT>Shows the dissatisfaction of true longs with all the negativity, short theses, bashing and down right crap found on the Yahoo board!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_164_3</DOCNO>
            	<TEXT>We now have 421 members in the Band with only a few undesirables mixed in.. The news released after the close was a shock to some, but something necessary to advance the programs and make the financial position stronger to be able to go it alone or to attract a minority partner.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_164_4</DOCNO>
            	<TEXT>Yes, our share price is lower, but our investment is stronger...... Enjoy this beautiful day...........</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_165_0</DOCNO>
            	<TEXT>Not unless they violate the rules mentioned in the introduction of the BANDOFBROTHERSOFSRNE.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_166_0</DOCNO>
            	<TEXT>The majority of the XBI is made up of small bios which are targets of the 'shorts', so the trending pps is very similar.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_166_1</DOCNO>
            	<TEXT>This attachment will be broken only when revenues come in to the extent that the 'shorts' will exit in droves to other more vulnerable targets.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_166_2</DOCNO>
            	<TEXT>I don't know when that day comes, but it will!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_167_0</DOCNO>
            	<TEXT>I believe tha yahoo board is under control of those shorts who are able to hack in and do as they wish.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_168_0</DOCNO>
            	<TEXT>Addressing the situation very well, thank you.......</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_169_0</DOCNO>
            	<TEXT>News Release today</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_169_1</DOCNO>
            	<TEXT># News Release # Sorrento Announces Publication of a Series of Novel SARS-CoV-2 Main Protease (MPRO) Inhibitors for Potential Treatment of COVID-19 Patients Infected With SARS-CoV-2 Variants Of Concern, Including Omicron December 5, 2021 at 2:28 PM EST[Download PDF](https://investors.sorrentotherapeutics.com/node/12861/pdf) * A representative of novel MPro inhibitor series, MPI8, dually inhibits MPro and cathepsin L, a key viral entry enzyme, with high potency and selectivity. *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_169_2</DOCNO>
            	<TEXT>Other analogs of the series have been evaluated by Sorrento to develop an oral antiviral drug for treatment of patients infected with existing and emerging SARS-CoV-2 variants of concern, including Omicron. *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_169_3</DOCNO>
            	<TEXT>A promising candidate of the series with unique features distinguished from SARS-CoV-2 MPro inhibitors published by others has been systematically evaluated and advanced to late stage of pre-clinical phase.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_169_4</DOCNO>
            	<TEXT>SAN DIEGO, Dec. 05, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, Sorrento) today announced the peer-reviewed publication of a series of novel SARS-CoV-2 MPro inhibitors with potent activities for both MPro and cathepsin L, a key host enzyme for SARS-CoV-2 entry into host cells, authored by Dr. Wenshe Ray Liu, professor at Texas A amp;M University.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_169_5</DOCNO>
            	<TEXT>The full manuscript is available at: [https://pubmed.ncbi.nlm.nih.gov/34242492/](https://www.globenewswire.com/Tracker?data=3wtf9TJp2k_Sh5u1GzLoVg4QPhjStf5FW1h_jAkxDQR5oFwPwKldV738Y2synUkv91hl9NGcdpGStGIT7X04F71mYolzNovQ19koJh7_D14Es1VH-5Wl_X6AmgSy4st-YU47rVCR4OJu5ImALjwa9A==) SARS-CoV-2 main protease (MPro) is a key enzyme for the viral life cycle including virus entry, replication and packaging.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_169_6</DOCNO>
            	<TEXT>MPro is highly conserved in all discovered SARS CoV-2 variants and is identified as a critical target for developing broad-spectrum antiviral drugs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_169_7</DOCNO>
            	<TEXT>In addition, experimental evidence has shown that certain host proteases prime the SARS-CoV-2 spike protein for viral packaging, interactions with ACE2, and viral entry into the host.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_169_8</DOCNO>
            	<TEXT>These include two serine proteases, furin and transmembrane protease serine 2 (TMPRSS2) and a cysteine protease cathepsin L. Small molecule medications that inhibit furin, TMPRSS2 and cathepsin L have shown efficacy in inhibiting SARS-CoV-2 replication.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_169_9</DOCNO>
            	<TEXT>In the publication, a representative analog of the series, MPI8, demonstrated dual inhibition of MPro and cathepsin L with high potency and selectivity (IC50 values for MPro and cathepsin L are 105 nM and 1.2 nM, respectively).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_169_10</DOCNO>
            	<TEXT>Sorrento has collaborated with Professor Lius lab at Texas A amp;M University to evaluate analogs in the series to develop an oral anti-COVID drug.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_169_11</DOCNO>
            	<TEXT>A promising analog with features distinguished from current reported SARS-CoV-2 MPro inhibitors has been systematically evaluated and advanced to a late stage of pre-clinical phase.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_169_12</DOCNO>
            	<TEXT>We are pleased to work with Prof. Lius group at Texas A amp;M University to develop a more effective oral MPro inhibitor to meet the urgent need for treatment of COVID-19 patients infected with existing and emerging variants.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_169_13</DOCNO>
            	<TEXT>The oral MPro inhibitor together with Sorrentos other ongoing therapeutic intervention approaches reflect our efforts to create amutation-agnostic global anti-COVID strategy to combat COVID-19 variants of concern, including the emerging Omicron variant, stated Dr. Henry Ji, Chairman and CEO of Sorrento.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_169_14</DOCNO>
            	<TEXT>As a selective inhibitor to both SARS-CoV-2 MPro and cathepsin L that is key to SARS-CoV-2 entry into the human host cell, MPI8 exerts improved potency to inhibit SARS-CoV-2.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_169_15</DOCNO>
            	<TEXT>So far it is potentially one of the most potent antivirals that have been developed to treat COVID-19, stated Dr. Wenshe Ray Liu, Gradipore Chair in the Department of Chemistry at Texas A amp;M University.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_170_0</DOCNO>
            	<TEXT>These positive news releases will come in at a more increasing rate as we go forward.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_170_1</DOCNO>
            	<TEXT>Ji has sowed the farm well, now we shall reap!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_171_0</DOCNO>
            	<TEXT>Good civil post.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_171_1</DOCNO>
            	<TEXT>Glad to see you're back on your meds after your rant yesterday... LOL</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_172_0</DOCNO>
            	<TEXT>Makes sense to hold back some parts of the news related to the contractual agreement, especially when you are expecting to ink additional contracts throughout Latin/South America......</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_173_0</DOCNO>
            	<TEXT>To keep a competitive advantage over your competitors as to particulars including volume and prices until you have secured the additional contracts you are negotiating.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_173_1</DOCNO>
            	<TEXT>It would be irresponsible for the company, to their investors, to release this info prior to finalizing agreements allowing a competitor to enter a more attractive offer.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_174_0</DOCNO>
            	<TEXT>Accreditation received</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_174_1</DOCNO>
            	<TEXT># News Release # Sorrento Therapeutics Clinical Laboratory Receives Accreditation From the College of American Pathologists December 7, 2021 at 9:00 AM EST[Download PDF](https://investors.sorrentotherapeutics.com/node/12881/pdf)**Sorrento has received accreditation from the American College of Pathologists, which allows Sorrento to bill to Medicare and Medicaid** SAN DIEGO, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to Sorrentos Clinical Laboratory, located in San Diego, California, based on results of a recent on-site inspection as part of the CAP's Accreditation Programs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_174_2</DOCNO>
            	<TEXT>Sorrentos clinical laboratory was advised of this national recognition and congratulated for the excellence of the services being provided.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_174_3</DOCNO>
            	<TEXT>The clinical laboratory is one of more than 8,000 CAP-accredited facilities worldwide.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_174_4</DOCNO>
            	<TEXT>This accreditation expands Sorrentos previously announced CLIA capabilities to include billing to Medicare and Medicaid for the analysis of patient samples.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_174_5</DOCNO>
            	<TEXT>Additionally, with the CLIA certification and CAP accreditation of its clinical laboratory, Sorrento has the capability to conduct timely clinical studies to support its product pipeline across all stages.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_174_6</DOCNO>
            	<TEXT>The U.S. federal government recognizes the CAP Laboratory Accreditation Program, begun in the early 1960s, as being equal-to or more-stringent-than the government's own inspection program.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_174_7</DOCNO>
            	<TEXT>During the CAP accreditation process, designed to ensure the highest standard of care for all laboratory patients, inspectors examine the laboratory's records and quality control of procedures for the preceding two years.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_174_8</DOCNO>
            	<TEXT>CAP inspectors also examine laboratory staff qualifications, equipment, facilities, safety program and record, and overall management. **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_174_9</DOCNO>
            	<TEXT>About the** **College of American Pathologists** As the world's largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_174_10</DOCNO>
            	<TEXT>For more information, READ THE CAP ANNUAL REPORT at [cap.org](http://cap.org/).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_175_0</DOCNO>
            	<TEXT>The ability to bill Medicare and other Gov't entities is quite the hurdle to have accomplished so quickly.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_175_1</DOCNO>
            	<TEXT>Should be looked upon as an endorsement.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_175_2</DOCNO>
            	<TEXT>Many bios take much longer to receive this.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_176_0</DOCNO>
            	<TEXT>After approval for knee pain, hopefully it will be available for off label treatment of lower back and shoulder pain, as I have, caused by arthritis....</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_177_0</DOCNO>
            	<TEXT>As I posted on yahoo, my flag was flown at half staff today to honor all those who were at Pearl on that infamous day back in 1941.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_177_1</DOCNO>
            	<TEXT>For those who we had lost and those survivors who were able to tell their first hand stories, so we will never forget...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_178_0</DOCNO>
            	<TEXT>Dr Ji knows we are close to a USA nod on Covi-stix, hence the new position posted for hire.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_178_1</DOCNO>
            	<TEXT>Although slower than all of us want, events are taking place in an orderly plan of action ..</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_179_0</DOCNO>
            	<TEXT>Acea Therapeutics and SmartPharm to date, with others to follow?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_180_0</DOCNO>
            	<TEXT>More great news! "</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_180_1</DOCNO>
            	<TEXT>got to love a plan when it comes together"...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_181_0</DOCNO>
            	<TEXT>If I had to bet on only 1 buyer, I would put my money on Moderna.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_181_1</DOCNO>
            	<TEXT>Large cash position and a tremendous amount of cash revenues coming in.... They want to expand their pipeline and become a much bigger Pharma.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_181_2</DOCNO>
            	<TEXT>Sorrento would fill that void immediately.....</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_182_0</DOCNO>
            	<TEXT>Couldn't ask for a more well connected and well respected Doctor to have on board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_182_1</DOCNO>
            	<TEXT>Semdexa, once approved, will be the sought after pain treatment for label and off label use.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_183_0</DOCNO>
            	<TEXT>Talk about a Santa Claus rally!!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_184_0</DOCNO>
            	<TEXT>Weekly summary.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_184_1</DOCNO>
            	<TEXT>Sorrento Therapeutics added the following items during the week of **December 6, 2021** #### All News Releases [Sorrento Announces Publication of a Series of Novel SARS-CoV-2 Main Protease (MPRO) Inhibitors for Potential Treatment of COVID-19 Patients Infected With SARS-CoV-2 Variants Of Concern, Including Omicron](http://url9490.notification.gcs-web.com/ls/click?upn=Vk1mmV-2F2BYXMSdrc2O0yE3dIdyJ36Qf-2BrVD74w8Wyr-2BJYIQfsy88dcRAv-2F2EJ6vIET4GgcfBMIk9tSVDdAPZV9Bcyz5l0t5Y1tg68Epn-2BsJxt2Qa7HN8Nuu46WqV7VpkPNOt86EKXmKaE4EyCmH0p1JY1OMhVt9MjQ8Gi5BeRKs7QxogxhA0p8HHpOBBCsNSZJ2w7-2Bmgq18sntRoCccBsQ-3D-3Drcir_DKMwEV5rE6ItJiX8ruKGZFPAKW3-2FBj8orHheDZHS-2F07idJuKH6yPcaZWWj7xUPGGayVhkKuBKp6-2BLMLXG9WESYznjCB8Z9QqQI612xxEsoLYt-2BShxVmNUfLoqqGWqGnvXwg7V2xxYUHpz36nU9AMdxBHfadeWJyFclsjNk6AEN14l7rxb17cr5H2t8P0ig7mri1vTmwsovHV4ULzY2o7lnV6Qfh1F1R6PF-2BOWN9IxYnVqcLUToY8qJmMqWaUHvdGtcQbs0YXWofc4jD6tn1Gfw-3D-3D) [Scilex Holding Company, a Sorrento Therapeutics Inc. Subsidiary, and Vickers Vantage Corp I (NASDAQ: VCKA) (SPAC) Enter into Letter of Intent for Proposed Business Combination](http://url9490.notification.gcs-web.com/ls/click?upn=Vk1mmV-2F2BYXMSdrc2O0yE3dIdyJ36Qf-2BrVD74w8Wyr-2BJYIQfsy88dcRAv-2F2EJ6vIET4GgcfBMIk9tSVDdAPZV9Bcyz5l0t5Y1tg68Epn-2BsKKcBFHARNior-2FjdacGMHEPjprs6x0eSihNg8OZ0UAcA4VTFFiaSpccXs0ELccg17EqMM2yfSKQg541KbvqQGTDLaNwFc5DnfrOQ6ZqbUcB1A-3D-3DEx31_DKMwEV5rE6ItJiX8ruKGZFPAKW3-2FBj8orHheDZHS-2F07idJuKH6yPcaZWWj7xUPGGayVhkKuBKp6-2BLMLXG9WESYznjCB8Z9QqQI612xxEsoLYt-2BShxVmNUfLoqqGWqGnvBi3E8vWRl4BgZfG-2Fcd-2FO-2BXiaNtk70MCW44yee6MyytvMSsWbICm0Q-2FGcLaiWKBYRUF-2FqnKz6at5aTFpdMsABsUUEm1ckfW4XrPH0inwaWnFgoGVOmGZ1SB0EVF3S8dg2NoT5SVjm5vRXS9qIEZ3Stg-3D-3D) [Sorrento Receives Orders of COVISTIX for Commercial Launch in Brazil](http://url9490.notification.gcs-web.com/ls/click?upn=Vk1mmV-2F2BYXMSdrc2O0yE3dIdyJ36Qf-2BrVD74w8Wyr-2BJYIQfsy88dcRAv-2F2EJ6vIET4GgcfBMIk9tSVDdAPZV9Bcyz5l0t5Y1tg68Epn-2BsIniftGSna5j50r4rl488ovMsf8XGMcYF9iSxxLqjJPEQS35kqUcmeGXOiuQvx7aSOduJXh4QNhrgIzdT3EQWuvrvLH4gMw9dM2aAeBGwSfIQ-3D-3DpRH6_DKMwEV5rE6ItJiX8ruKGZFPAKW3-2FBj8orHheDZHS-2F07idJuKH6yPcaZWWj7xUPGGayVhkKuBKp6-2BLMLXG9WESYznjCB8Z9QqQI612xxEsoLYt-2BShxVmNUfLoqqGWqGnvsHUjpFj1maG2ODxuSw4r8IlU1pqWyoCmM3Vs-2BeitKWWDzG2n9YdSoYGMnHdTXy-2BSQtVFk-2FP5taA1q-2B0m0AUcPH4emvTZDLDsyzHRXmMdRTyBxKOfpL1H3cp3nrCQjKmj4vKiwfrMfN-2FULdA-2F-2FCuKXQ-3D-3D) [Sorrento Therapeutics Clinical Laboratory Receives Accreditation From the College of American Pathologists](http://url9490.notification.gcs-web.com/ls/click?upn=Vk1mmV-2F2BYXMSdrc2O0yE3dIdyJ36Qf-2BrVD74w8Wyr-2BJYIQfsy88dcRAv-2F2EJ6vIET4GgcfBMIk9tSVDdAPZV9Bcyz5l0t5Y1tg68Epn-2BsIvori-2BwbwK3CIoqyUzrrYJFXXec4CJ7pZYpke7VR0AwSz8hhjenrhq6D-2Fcfag63qIbY2chigW4rY-2FQkt8gBTOtqbDL7DiC04z4RJpHTjmtvA-3D-3Dpib9_DKMwEV5rE6ItJiX8ruKGZFPAKW3-2FBj8orHheDZHS-2F07idJuKH6yPcaZWWj7xUPGGayVhkKuBKp6-2BLMLXG9WESYznjCB8Z9QqQI612xxEsoLYt-2BShxVmNUfLoqqGWqGnvXqlWGVPmwVHG-2BMbNVkpCqGmSK36ZvM-2BdRRN5DbgF3d4h4VTsnnbpU-2Fv-2FNlmuqrJ3S3RPradBQNIOlXmAZySAXK52JOdwQF16us52kQXHlRx6QsioE-2B98f3RtYwFcNZq6T-2FPGyGY196-2F-2BalwJtDT1lQ-3D-3D) [Sorrento Begins Enrollment in Phase 2 Trial of Resiniferatoxin (RTX) for the Treatment of Pain Due to Knee Osteoarthritis (OA)](http://url9490.notification.gcs-web.com/ls/click?upn=Vk1mmV-2F2BYXMSdrc2O0yE3dIdyJ36Qf-2BrVD74w8Wyr-2BJYIQfsy88dcRAv-2F2EJ6vIET4GgcfBMIk9tSVDdAPZV9Bcyz5l0t5Y1tg68Epn-2BsLiXWdfOgLSUvsckULd8lCRuJP-2FRc2CE1Qh-2B8HVedBrdFtKhGkmEW58zQM5vNcFecx6p8Ndps2kedS2sggIcblqu4YJ-2B038KKI-2FJQG-2B362O8Q-3D-3Dkb5R_DKMwEV5rE6ItJiX8ruKGZFPAKW3-2FBj8orHheDZHS-2F07idJuKH6yPcaZWWj7xUPGGayVhkKuBKp6-2BLMLXG9WESYznjCB8Z9QqQI612xxEsoLYt-2BShxVmNUfLoqqGWqGnvFrPkKxYUr2dRawx2BihVv1WEHbsoDWvjWi5627raetWTvLiZLRbzNdSjDxbtVya0DiHDv21-2F9FjwDNIvq-2FfufRY1SDPyMGcXoVfcs8zJeQK5gfjj-2BRgRTO7OCbt-2BIyN5e92zydY3wuA8LsLl-2Fol2jA-3D-3D) [Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary, Announces Highly Significant Positive Top-Line Results from its Phase 3 Non-Opioid Injectable SP-102 (SEMDEXA) Pivotal Trial C.L.E.A.R. Program for Sciatica Pain Management Supporting the](http://url9490.notification.gcs-web.com/ls/click?upn=Vk1mmV-2F2BYXMSdrc2O0yE3dIdyJ36Qf-2BrVD74w8Wyr-2BJYIQfsy88dcRAv-2F2EJ6vIET4GgcfBMIk9tSVDdAPZV9Bcyz5l0t5Y1tg68Epn-2BsKKcBFHARNior-2FjdacGMHEPjprs6x0eSihNg8OZ0UAcA4VTFFiaSpccXs0ELccg17EqMM2yfSKQg541KbvqQGTDedocX-2BbLLuWE0QsO3jFZPQ-3D-3DMENG_DKMwEV5rE6ItJiX8ruKGZFPAKW3-2FBj8orHheDZHS-2F07idJuKH6yPcaZWWj7xUPGGayVhkKuBKp6-2BLMLXG9WESYznjCB8Z9QqQI612xxEsoLYt-2BShxVmNUfLoqqGWqGnvN3BtLkbdrqtPJCAW9-2FYm8zo-2FxyJaykbFuwS3KJjGlCLMWI1fF-2F51MVddSHtQg4Mf-2BRJhdzofvJ0sG68FRt4-2BtMkNAFya9yMe-2BB16ROGXPj1Gqczv1CcBTz-2FgjNpA3G3ybbK-2FeKVQI7-2F8R8yDPJi9uA-3D-3D)  A lot took place this past week.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_184_2</DOCNO>
            	<TEXT>I believe we saw the low and recovered nicely.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_184_3</DOCNO>
            	<TEXT>Did you take advantage of the sale price early in the week as I did?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_185_0</DOCNO>
            	<TEXT>We opened Monday at $5.00, saw a low of $4.69 on Monday, and closed today at $6.20 up 24% for the week.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_185_1</DOCNO>
            	<TEXT>Up 32% from the low of $4.69...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_186_0</DOCNO>
            	<TEXT>That's what I was going to wear!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_186_1</DOCNO>
            	<TEXT>Now I'll have to think of something else............</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_187_0</DOCNO>
            	<TEXT>Excellent Sunday morning refresher!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_187_1</DOCNO>
            	<TEXT>Most, if not all, Covid related stocks have been beaten down over the past 2 to 4 weeks including the benchmark XBI.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_187_2</DOCNO>
            	<TEXT>SRNE has broken that trend by rebounding nicely this past week while the others in this space have dropped further.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_187_3</DOCNO>
            	<TEXT>I expect additional news releases this upcoming week to continue this trending upward rise in the pps......</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_188_0</DOCNO>
            	<TEXT>This nut case is permanently off his meds and should seek help, but it's not our job to provide it!!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_189_0</DOCNO>
            	<TEXT>Great videos showing how RTX works and a very greatfull "Scooter"!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_190_0</DOCNO>
            	<TEXT>New 8K today</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_190_1</DOCNO>
            	<TEXT>**FORM** **8-K** **CURRENT REPORT** **PURSUANT TO SECTION 13 OR 15(d)** **OF THE SECURITIES EXCHANGE ACT OF 1934** **Date of Report (Date of earliest event reported):** **December 13, 2021** **SORRENTO THERAPEUTICS, INC.** **(</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_190_2</DOCNO>
            	<TEXT>Exact Name of Registrant as Specified in its Charter)** **Delaware** **001-36150** **33-0344842** **(State or Other Jurisdiction** **of Incorporation)** **(Commission** **File Number)** **(IRS Employer** **Identification No.)** **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_190_3</DOCNO>
            	<TEXT>4955 Directors Place** **San Diego,** **CA** **92121** **(Address of Principal Executive Offices) (Zip Code)** **Registrants telephone number, including area code: (858)** **203-4100** **N/A** **(Former Name, or Former Address, if Changed Since Last Report)** Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities Registered pursuant to Section 12(b) of the Act: **Title of each class** **Trading Symbol** **Name of each exchange on which registered**Common Stock, $0.0001 par value SRNE The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_190_4</DOCNO>
            	<TEXT>Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_190_5</DOCNO>
            	<TEXT>Item 8.01 Other Information**.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_190_6</DOCNO>
            	<TEXT>On December 13, 2021, Scilex Holding Company (Scilex), a majority-owned subsidiary of Sorrento Therapeutics, Inc., posted under the Product Portfolio-Publications section of Scilexs website at www.scilexpharma.com a corporate presentation.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_190_7</DOCNO>
            	<TEXT>Representatives of Scilex expect to use the presentation in industry conferences, investor conferences and investor meetings from time to time.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_190_8</DOCNO>
            	<TEXT>A copy of the presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_190_9</DOCNO>
            	<TEXT>Financial Statements and Exhibits.** (</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_190_10</DOCNO>
            	<TEXT>d)Exhibit. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_190_11</DOCNO>
            	<TEXT>99.1](https://investors.sorrentotherapeutics.com/node/12901/html#tm2135241d1_ex99-1.htm)[Scilex Holding Company Corporate Presentation (December 2021).](https://investors.sorrentotherapeutics.com/node/12901/html#tm2135241d1_ex99-1.htm)104Cover Page interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_191_0</DOCNO>
            	<TEXT>Certainly has been in the past...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_192_0</DOCNO>
            	<TEXT>Yes, saw that and agree that the big investors will be adding after the new year begins.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_192_1</DOCNO>
            	<TEXT>2022 will be an exciting year for Sorrento and it's shareholders.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_193_0</DOCNO>
            	<TEXT>Lately it seems we are playing "Chutes  amp; Ladders"!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_193_1</DOCNO>
            	<TEXT>But that is about to change!!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_193_2</DOCNO>
            	<TEXT>We are about to be playing Monopoly with all 4 corners as "GO" and no jail!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_194_0</DOCNO>
            	<TEXT>Nice find, thanks...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_195_0</DOCNO>
            	<TEXT>Very interesting find.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_196_0</DOCNO>
            	<TEXT>Therapeutics Tracker</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_196_1</DOCNO>
            	<TEXT># COVID-19 therapeutics tracker Posted 10 December 2021 | By [Jeff Craven](https://www.raps.org/news-and-articles/news-articles?author=345d8d0c-6d83-4c23-8563-a004254f5f03) A handful of therapeutics have been approved specifically to treat COVID-19 in different countries around the world.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_196_2</DOCNO>
            	<TEXT>Among those treatments are dexamethasone, Avigan (favilavir), Veklury (remdesivir), Lagevrio (molnupiravir),Xevudy (sotrovimab), Regkirona (regdanvimab), and Ronapreve (casirivimab and imdevimab).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_196_3</DOCNO>
            	<TEXT>Regulators around the world have allowed additional treatments to be used on an emergency-use basis.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_196_4</DOCNO>
            	<TEXT>This tracker will be updated biweekly with the latest in developments for treatment candidates who have advanced to at least Phase 1 study.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_196_5</DOCNO>
            	<TEXT>If you notice an issue with this data or wish to submit an update, please email*Regulatory Focus*at[news@raps.org](mailto:news@raps.org). *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_196_6</DOCNO>
            	<TEXT>Updated 10 December* with new information about Lagevrio (molnupiravir), Evusheld, Regkirona, Actemra/RoActemra, amubarvimab/romlusevimab, heparin, Vascepa, Paxlovid, Xevudy, bamlanivimab + etesevimab, lenzilumab, and convalescent plasma.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_196_7</DOCNO>
            	<TEXT>Please note this will be the last update of the *Regulatory Focus* COVID-19 therapeutics tracker for 2021.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_196_8</DOCNO>
            	<TEXT>Our next update will be published on 7 January 2022. **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_196_9</DOCNO>
            	<TEXT>SHOW/HIDE STUDY DESIGN  amp; DETAILS** **Show** **102550100** **entriesSearch:Medication classTrade name (generic name)Developer/ResearcherSponsorTrial PhaseLast update**AntiviralMolnupiravir (Lagevrio, formerly known as MK-4482 and EIDD-2801)[Ridgeback Biotherapeutics](https://ridgebackbio.com/); [Merck](https://www.merck.com/index.html)[Ridgeback Biotherapeutics](https://ridgebackbio.com/); [Merck](https://www.merck.com/index.html)Phase 310-Dec-2021Monoclonal antibodyEvusheld (tixagevimab and cilgavimab; AZD7442)[AstraZeneca](https://www.astrazeneca.com/); [Vanderbilt University Medical Center](https://www.vumc.org/)[AstraZeneca](https://www.astrazeneca.com/); BARDAPhase 310-Dec-2021Monoclonal antibodyRegkirona (regdanvimab, CT-P59)CelltrionCelltrionPhase 310-Dec-2021IL-6 receptor agonistActemra/RoActemra (tocilizumab)[Roche](https://www.roche.com/)VariousPhase 310-Dec-2021Monoclonal antibodyAmubarvimab and romlusevimab (formerly BRII-196 and BRII-198)Brii Biosciences LimitedNIAIDPhase 310-Dec-2021AnticoagulantHeparin (UF and LMW)NHLBIOperation Warp Speed; University of PittsburghPhase 2/3/410-Dec-2021Lipid-lowering agentVascepa (icosapent ethyl)[Amarin Corporation](https://amarincorp.com/)Amarin Pharma Inc.; Kaiser Permanente; Estudios Clnicos Latino Amrica; Canadian Medical and Surgical Knowledge Translation Research GroupPhase 2/3/410-Dec-2021AntiviralPaxlovid (PF-07321332) + ritonavirPfizerPfizerPhase 2/310-Dec-2021Monoclonal antibodySotrovimab, also known as Xevudy (VIR-7831, GSK4182136)GSK, Vir BiotechnologyGlaxoSmithKlinePhase 2/310-Dec-2021Monoclonal antibodiesBamlanivimab + etesevimab[Lilly](https://www.lilly.com/); [Junshi Biosciences](http://junshipharma.com/en/Index.html)[Lilly](https://www.lilly.com/); [Junshi Biosciences](http://junshipharma.com/en/Index.html); Operation Warp SpeedPhase 2/310-Dec-2021Monoclonal antibodyLenzilumab[Humanigen](https://www.humanigen.com/); [Catalent](https://www.catalent.com/)NIAIDPhase 2/310-Dec-2021ImmunoglobulinConvalescent plasmaVariousVariousPhase 1/210-Dec-2021Antibody cocktailCasirivimab/imdevimab (REGEN-COV, REGN-COV2)[Regeneron](https://www.regeneron.com/); Cipla; [Roche](https://newsroom.regeneron.com/news-releases/news-release-details/regeneron-and-roche-collaborate-significantly-increase-global)[Regeneron](https://www.regeneron.com/)Phase 2/319-Nov-2021AntiviralAT-527Atea Pharmaceuticals, Inc.Atea Pharmaceuticals, Inc.Phase 2/319-Nov-2021Synthetic human vasoactive intestinal peptide (VIP)Zyesami (aviptadil, RLF-100)[NRx Pharmaceuticals](http://www.neurorxpharma.com/); [Relief Therapeutics](https://relieftherapeutics.com/)[NRx Pharmaceuticals](http://www.neurorxpharma.com/)Phase 2/319-Nov-2021IL-6 receptor agonistKevzara (sarilumab)[Sanofi](https://www.sanofi.com/); [Regeneron](https://www.regeneron.com/)[Sanofi](https://www.sanofi.com/); [Regeneron](https://www.regeneron.com/)Phase 2/319-Nov-2021AntiviralEnsovibep (MP0420)Molecular Partners; NovartisMolecular Partners; NovartisPhase 2/319-Nov-2021Tyrosine kinase inhibitorSTI-5656 (abivertinib)[Sorrento Therapeutics](https://sorrentotherapeutics.com/)[Sorrento Therapeutics](https://sorrentotherapeutics.com/)Phase 219-Nov-2021 #### Study Design  amp; Details **Background**: Sorrento Therapeutics is testing a tyrosine kinase inhibitor STI-5656 (abivertinib maleate) in patients hospitalized with COVID-19 related pneumonia.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_196_10</DOCNO>
            	<TEXT>The company licensed abivertinib from ACEA Therapeutics as a [therapy](https://www.bioworld.com/articles/471740-sorrento-advances-abivertinib-for-hospitalized-patients-aiming-for-full-covid-19-cycle) for COVID-19. **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_196_11</DOCNO>
            	<TEXT>Trials**: A Phase 2 trial of 80 participants receiving STI-5656 or standard of care in the US ([NCT04440007](https://clinicaltrials.gov/ct2/show/NCT04440007)), and a Phase 2 trial of up to 400 participants in Brazil ([NCT04528667](https://clinicaltrials.gov/ct2/show/NCT04528667)) have been completed. **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_196_12</DOCNO>
            	<TEXT>Outcomes**: Preliminary results from the Phase 2 trial in the US showed patients in the STI-5656 group had a 20% improvement in avoiding respiratory failure and death at 1 month compared with placebo (78.3% vs. 58.3%).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_196_13</DOCNO>
            	<TEXT>In the study located in Brazil, patients in the STI-5656 group had a 25% improvement in avoiding respiratory failure and death at 1 month compared with placebo (69.6% vs. 44.4%).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_196_14</DOCNO>
            	<TEXT>Results from both trials were announced in a [press release](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/update-sorrento-announces-encouraging-results-two-phase-2) by Sorrento Therapeutics. **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_196_15</DOCNO>
            	<TEXT>Status**: A Phase 3 trial is being planned based on positive results from both Phase 2 trials, according to the company.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_197_0</DOCNO>
            	<TEXT>COVISTIX = Sorrento buy Recommendation</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_197_1</DOCNO>
            	<TEXT>## Good news for COVISTIX In the last weeks, COVISTIX - one of Sorrentos main products received some important approvals that could be the starting point for a new (and solid) revenue stream.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_197_2</DOCNO>
            	<TEXT>First of all, COVISTIX the COVID19 rapid antigen detection test [received the CE Mark](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-covistixtm-covid-19-virus-rapid-antigen): the importance of such approval is invaluable since, as the European Commission website reports,  gt;*the letters CE appear on many products traded on the extended Single Market in the European Economic Area (EEA).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_197_3</DOCNO>
            	<TEXT>They signify that products sold in the EEA have been assessed to meet high safety, health, and environmental protection requirements*.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_197_4</DOCNO>
            	<TEXT>For a company that wants to sell its products in EU having a CE Mark is a necessary condition: therefore, the fact that Sorrento Therapeutics asked for a CE mark means that the Company is seriously taking into consideration the EU market.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_197_5</DOCNO>
            	<TEXT>The first European country where COVISTIX could be sold is Belgium where the FAMHP (Federal Agency for Medicines and Health Products) granted a marketing authorization.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_197_6</DOCNO>
            	<TEXT>About one week ago, COVISTIX received [another relevant approval](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-receives-brazilian-health-regulatory-agency-anvisa), this time from the Brazilian Health Regulatory Agency.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_197_7</DOCNO>
            	<TEXT>The Brazilian authority approved both the manufacturing and marketing of COVISTIX: according to a press release, Sorrento is already establishing local distribution agreements and is processing the first purchase orders.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_197_8</DOCNO>
            	<TEXT>I believe that this news can potentially have a huge impact on Sorrento Therapeutics financials since Brazil is one of the countries most affected by COVID.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_197_9</DOCNO>
            	<TEXT>To give an idea, according to [Worldometers](https://www.worldometers.info/coronavirus/), Brazil has almost reached 22 million total cases with ca.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_197_10</DOCNO>
            	<TEXT>64 million COVID tests performed so far.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_197_11</DOCNO>
            	<TEXT>Moreover, [40%](http://ourworldindata.org/covid-vaccinations) of the Brazilian population still has not been covered by the vaccine and therefore, testing activity is likely to be fundamental in the next months.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_197_12</DOCNO>
            	<TEXT>Overall, I think that it is easily understandable the big opportunity represented by the Brazilian market. ##</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_197_13</DOCNO>
            	<TEXT>Conclusion In conclusion, I believe that the results reported by Sorrento Therapeutics are nothing special, meaning that they will act neither as a positive nor negative catalyst for the stock price.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_197_14</DOCNO>
            	<TEXT>On the other hand, I think that the new business opportunity represented by COVISTIX - in EU but mostly in Brazil is going to act as a massive boost on Sorrentos revenues supporting stock price growth.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_197_15</DOCNO>
            	<TEXT>This is why I believe that, at the current stock price of 6.18 $/share, SRNE is worth a buy recommendation.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_198_0</DOCNO>
            	<TEXT>Another key team position created to move forward into a big Pharma through acquisitions and/or partnerships....</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_0</DOCNO>
            	<TEXT>My thoughts and feelings on the state of affairs.....</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_1</DOCNO>
            	<TEXT>This post has nothing to do with Sorrento, but falls under my 'Freedom of Speech'.. I do hope all would agree with me... It is a fact of life in our country today that there are people who live to be offended.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_2</DOCNO>
            	<TEXT>They're called Progressives.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_3</DOCNO>
            	<TEXT>They are offended by Confederate statues and the Confederate Flag, by monuments that they say celebrate white supremacy and colonialism, by Trump supporters, by Trump himself, and by those who refuse to get on their knees and grovel before Black Lives Matter.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_4</DOCNO>
            	<TEXT>Well, I am not one of them, and I've got a big revelation for them.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_5</DOCNO>
            	<TEXT>Here are **ten** things for which I will never apologize, and I don't give sour owls waste if anyone is offended by any of them. **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_6</DOCNO>
            	<TEXT>I'm white - I was born white and I don't feel guilty about slavery, segregation, the Trail of Tears or the treatment of Chinese railroad workers - because (now get this) I didn't have anything to do with any of these.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_7</DOCNO>
            	<TEXT>It is history and you cant change it.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_8</DOCNO>
            	<TEXT>I'm no more responsible for these injustices than the Indian of today is responsible for the Black Hole of Calcutta.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_9</DOCNO>
            	<TEXT>The idea of racial guilt is absurd.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_10</DOCNO>
            	<TEXT>White privilege and white supremacy is a myth.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_11</DOCNO>
            	<TEXT>Where is the White Miss America Contest, White History Month and White Entertainment Television?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_12</DOCNO>
            	<TEXT>Where are the white-only colleges and universities, white-only dating sites or white-only bars and restaurants?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_13</DOCNO>
            	<TEXT>Where are the quotas and set-asides for Caucasians?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_14</DOCNO>
            	<TEXT>Do we need to address these things?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_15</DOCNO>
            	<TEXT>To some degree, yes, but not by rioting, tearing down statues, looting and destroying businesses, changing names of sports teams and products.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_16</DOCNO>
            	<TEXT>We can and should address these things with civility and dialogue by all concerned. **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_17</DOCNO>
            	<TEXT>I love America - I believe in American exceptionalism.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_18</DOCNO>
            	<TEXT>America pioneered representative government guided by a written constitution.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_19</DOCNO>
            	<TEXT>We fought a war with 620,000 dead to end slavery.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_20</DOCNO>
            	<TEXT>We defeated Nazi Germany and Imperial Japan and liberated the death camps.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_21</DOCNO>
            	<TEXT>We saved Europe from tyranny, twice, in the 20th century and then, with American investment, innovation, resourcefulness and generosity, rebuilt the economies of 17 nations of Europe and the nation of Japan.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_22</DOCNO>
            	<TEXT>Our arms kept communism from conquering the world.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_23</DOCNO>
            	<TEXT>Our factories and workshops produced a flood of inventions and products that benefited humanity.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_24</DOCNO>
            	<TEXT>We built the greatest most respected medical system in the world and earned more Nobel Prizes in Medicine than any other nation on earth by a factor of ten!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_25</DOCNO>
            	<TEXT>What country has done as much - especially in 244 years, a relative hiccup in time? **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_26</DOCNO>
            	<TEXT>I'm a Christian - I love God and his son Jesus Christ.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_27</DOCNO>
            	<TEXT>I am proud of my faith, but I do not wear it on my sleeve.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_28</DOCNO>
            	<TEXT>I respect all religions.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_29</DOCNO>
            	<TEXT>I also believe in the State of Israel.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_30</DOCNO>
            	<TEXT>Modern Israel is a miracle and a fulfillment of Biblical prophecy.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_31</DOCNO>
            	<TEXT>Israel is a beleaguered outpost of civilization in a savage region and a bulwark against the forces of darkness.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_32</DOCNO>
            	<TEXT>The next time your physician gives you a shot of penicillin, look up who discovered this miracle drug. **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_33</DOCNO>
            	<TEXT>My heroes include George Washington, Thomas Jefferson, Andrew Jackson, Abraham Lincoln, Teddy Roosevelt - Washington and Lincoln were indispensable men.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_34</DOCNO>
            	<TEXT>Washington defeated the greatest army on earth and led our country for the first quarter-century of its existence.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_35</DOCNO>
            	<TEXT>Lincoln saved the Union, abolished slavery and inspired generations with his rhetoric.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_36</DOCNO>
            	<TEXT>The Declaration of Independence flames with the eloquence of Thomas Jefferson, arguably the most intelligent man to ever serve as President of the United States.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_37</DOCNO>
            	<TEXT>Andrew Jackson, the hero of the Battle of New Orleans, represented the pioneer spirit.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_38</DOCNO>
            	<TEXT>Teddy Roosevelt led the charge into the 20th century, the American Century.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_39</DOCNO>
            	<TEXT>Together, they gave us a country so free that malcontents like Bernie Sanders, Alexandria Ocasio-Cortez, Ilhan Omar, Rashida Talib and Ayanna Pressley can dump on it without fear of reprisal.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_40</DOCNO>
            	<TEXT>As representatives of the American people they are a disgrace to our nation.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_41</DOCNO>
            	<TEXT>They all incite turmoil and division in our country.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_42</DOCNO>
            	<TEXT>They are most certainly Anti-American.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_43</DOCNO>
            	<TEXT>Indeed, if you listen to all the complaints voiced from all the liberal/progressive democrats and communists like NYC Mayor Bill De Blasio, you are hard pressed to understand why there are so few people leaving our country!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_44</DOCNO>
            	<TEXT>It is harder still to understand why, with all of our so called "problems", millions of people from around the world want to come here! **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_45</DOCNO>
            	<TEXT>I support our Police, and I believe police officers are generally decent/honorable men and women who are doing a difficult, dangerous, often thankless job - You couldn't pay me enough today to do it.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_46</DOCNO>
            	<TEXT>Besides risking their lives every time they go to work, they bear the added burden of listening to insults shouted at them by spoiled, ungrateful people many of whom are wet behind their ears and probably still wearing diapers.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_47</DOCNO>
            	<TEXT>Police today have become the punching bag for the nation and, sadly, they receive little or no respect or support from their superiors and the gaggle of incompetent democratic mayors around the country.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_48</DOCNO>
            	<TEXT>And, like our military, they are all that stands between us and the abyss.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_49</DOCNO>
            	<TEXT>When the Twin Towers were attacked in New York City on 9/11, we were reminded by liberals to not judge all Muslims by the actions of a few.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_50</DOCNO>
            	<TEXT>Yet today, mobs are willing to judge all police by the actions of a few police.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_51</DOCNO>
            	<TEXT>Explain that one to me.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_52</DOCNO>
            	<TEXT>Defunding the police because of a few "bad apples" is just plain STUPID because the end result will be more crime.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_53</DOCNO>
            	<TEXT>If you find that difficult to comprehend, just check the crime statistics for these liberal democratic controlled cities: New York, Chicago, Minneapolis, Los Angeles, San Francisco, St. Louis, Newark, Trenton and check out the number of shootings and stabbings on any given weekend!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_54</DOCNO>
            	<TEXT>You would think these cities are in a war zone. **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_55</DOCNO>
            	<TEXT>I support the Second Amendment, and I own weapons - It's one of the reasons why Japan thought long and hard about attacking us It's a major reason why we'll never have a Holocaust here.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_56</DOCNO>
            	<TEXT>Europe has had the divine right of kings, religious persecution, Communism and Nazism.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_57</DOCNO>
            	<TEXT>We have the Second Amendment.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_58</DOCNO>
            	<TEXT>The anarchy in our streets, coupled with calls to defund the police, only serve to underscore the need for civilian gun ownership. **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_59</DOCNO>
            	<TEXT>Reparations are racial plunder.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_60</DOCNO>
            	<TEXT>The idea of racial guilt is an obscenity from the dark recesses of 19th century European history - There's no group in the world that hasn't been oppressed at some point in time.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_61</DOCNO>
            	<TEXT>Will Denmark pay reparations to the English for the Danelaw?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_62</DOCNO>
            	<TEXT>Will Mongols and Manchus compensate the Chinese?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_63</DOCNO>
            	<TEXT>Will Japan compensate the Chinese for the Rape of Nanjing?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_64</DOCNO>
            	<TEXT>How about the English and the Irish, the Mongols and the Russians, the Cossacks and Jews?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_65</DOCNO>
            	<TEXT>Will bi-racial Barack Obama take money out of one pocket and put it in another? **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_66</DOCNO>
            	<TEXT>There are only two genders.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_67</DOCNO>
            	<TEXT>Deal with it - Gender is determined at birth by your DNA.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_68</DOCNO>
            	<TEXT>Just as you can't change your DNA, you can't change your sex.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_69</DOCNO>
            	<TEXT>You should not be able to force others to participate in your fantasy.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_70</DOCNO>
            	<TEXT>Reality isn't hateful. **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_71</DOCNO>
            	<TEXT>I support what President Trump advocated and accomplished during his four years in office.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_72</DOCNO>
            	<TEXT>The 45th president loves this country.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_73</DOCNO>
            	<TEXT>He had Israel's back.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_74</DOCNO>
            	<TEXT>Who else was strong enough to stand up to China and Iran?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_75</DOCNO>
            	<TEXT>Unlike almost everyone else in Washington, as a businessman, he understood finance and the market economy.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_76</DOCNO>
            	<TEXT>He's gave us judges who deliberate instead of legislate.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_77</DOCNO>
            	<TEXT>And he had the guts not to be liked.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_78</DOCNO>
            	<TEXT>Prior to COVID-19, President Trump built the greatest most prosperous economy in the world and he gave power back to the people.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_79</DOCNO>
            	<TEXT>He understood that we are a people who happen to have a government, not the other way around, and this American experiment in which government derives its just power from the consent of the governed is still the most unique, treasured and progressive form of government in the history of mankind.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_80</DOCNO>
            	<TEXT>He may or may not be the best candidate in 2024, but his policies should be followed by the Republican nominee, whoever that might be. **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_81</DOCNO>
            	<TEXT>You have a right to disagree with me, but you do not have a right to try to silence me - Being offended doesn't trump the First Amendment.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_82</DOCNO>
            	<TEXT>Attacking statues and assaulting those with different values is the kind of thing we saw in Nazi Germany and Stalin's Russia.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_83</DOCNO>
            	<TEXT>Generations of Americans died for freedom of speech, not freedom to suppress speech.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_84</DOCNO>
            	<TEXT>To say you're offended is merely an attempt to prioritize your feelings above everyone and everything else.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_85</DOCNO>
            	<TEXT>It's not an argument, but a call to end discussion - an admission of intellectual impotence.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_86</DOCNO>
            	<TEXT>Being offended isn't a mark of virtue; it's a sign that you're a big, blubbering baby who will throw a tantrum if you can't get your way.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_87</DOCNO>
            	<TEXT>Wagging fingers and shouting obscenities at me is just plain disrespectful and might get you a punch in the nose.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_88</DOCNO>
            	<TEXT>Sadly, that is what we see today with liberals and progressives.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_89</DOCNO>
            	<TEXT>They do not maintain a dialogue, they respond with insults and attacks, and that is fundamentally because they have not done their homework, are poorly educated, lack historical perspective, and context and have no inclination or desire to reason.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_90</DOCNO>
            	<TEXT>We have the right to disagree... but what I see taking place in our country today is simply not right from any reasonable perspective.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_91</DOCNO>
            	<TEXT>Many in politics have lost their sanity for political reasons.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_92</DOCNO>
            	<TEXT>I heard AOC state this morning that the riots and looting are taking place because of the pandemic.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_93</DOCNO>
            	<TEXT>People don't have food, so they must riot.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_94</DOCNO>
            	<TEXT>Does anyone believe this drivel?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_95</DOCNO>
            	<TEXT>For what food were they looking at Dick's Sporting Goods, Macys, Gucci, Louis Vuitton, etc.?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_199_96</DOCNO>
            	<TEXT>I may be wrong, but I would bet that the Reverend Martin Luther King, Jr. is looking down from Heaven at all the rioting looting, black on black killing, BLM and saying to himself, "I can't believe I died for this.'..</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_200_0</DOCNO>
            	<TEXT>Sitting in my office this afternoon listening to the news shows describing disgusting conditions in our country which are being allowed to increase almost daily, I was compelled to post this.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_200_1</DOCNO>
            	<TEXT>Too many people are silent on these issues especially those in positions of having the power to reverse the path we are on.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_200_2</DOCNO>
            	<TEXT>It was not intended to offend anyone, I was venting my frustrations as I have watched for the past few years as our great nation's moral values are circling the drain..... Maybe I should not have posted it, but I felt I had to..............</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_201_0</DOCNO>
            	<TEXT>You can be a majority of one when you are in the right!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_201_1</DOCNO>
            	<TEXT>Always stand tall in your values....</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_202_0</DOCNO>
            	<TEXT>Barney, wow, please seek serious mental help asap and take steve with you...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_203_0</DOCNO>
            	<TEXT>Excellent post of true facts, thanks for expressing my feelings so well.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_204_0</DOCNO>
            	<TEXT>Covid stocks</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_204_1</DOCNO>
            	<TEXT>Almost all Covid related stocks are up strong today at noon EST.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_204_2</DOCNO>
            	<TEXT>This is good news for investors, but not so good for the nation as the spread of the virus is increasing as cold weather returns.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_204_3</DOCNO>
            	<TEXT>The media is not helping as one talking head says there is nothing to be concerned about and then 10 minutes later another says the sky is falling. '</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_204_4</DOCNO>
            	<TEXT>Filp-Flop' Fauci is leading the charge of confusion....</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_205_0</DOCNO>
            	<TEXT>Yes, and the outcome is the same!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_206_0</DOCNO>
            	<TEXT>I too was surprised of the lack of response by the current analysts covering Sorrento.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_206_1</DOCNO>
            	<TEXT>Not necessarily a target price increase but a reinforcement of their current targets.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_206_2</DOCNO>
            	<TEXT>Also surprised to not see comments from other analysts who possibly have been sitting on the sidelines eyeing the news releases as they have been coming weekly.. Expecting the above in the near future.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_207_0</DOCNO>
            	<TEXT>I was a combat medic in the Central Highlands out of Dak to 67 to 69.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_207_1</DOCNO>
            	<TEXT>How would you read of my service?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_207_2</DOCNO>
            	<TEXT>I did not publish it and was not serving as "Biomaniac"!!!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_208_0</DOCNO>
            	<TEXT>I see the 311 log command was changed to the 311th Support Brigade in 1974.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_208_1</DOCNO>
            	<TEXT>In spite of your rudeness, I thank you for your service!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_209_0</DOCNO>
            	<TEXT>10 to 11 million off label injections, some of which I receive twice per year, is a market ripe for the taking.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_209_1</DOCNO>
            	<TEXT>A non opioid pain preventive injection will be the choice of patients and their doctors.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_209_2</DOCNO>
            	<TEXT>2022 is looking better all the time.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_210_0</DOCNO>
            	<TEXT>Very good and appropriate read on this Sunday.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_210_1</DOCNO>
            	<TEXT>Sorrento will be blessed as will all those who will benefit from what comes from the science, innovation and efforts of this great company which we are part of as investors.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_211_0</DOCNO>
            	<TEXT>A very limited and minimal amount of research will answer that question for yourself....</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_212_0</DOCNO>
            	<TEXT>He has a post history of trashing other's posts.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_213_0</DOCNO>
            	<TEXT>Magic button......</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_214_0</DOCNO>
            	<TEXT>I have had surgery 15 years ago for kidney uric acid stones.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_214_1</DOCNO>
            	<TEXT>I first invested in Sorrento back in Sept of 2020.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_215_0</DOCNO>
            	<TEXT> Apology certainly accepted.. Your friend sounds like he was a great man, definitely was a hero for sure.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_215_1</DOCNO>
            	<TEXT>I have lost friends over the years to Agent Orange.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_215_2</DOCNO>
            	<TEXT>I had heard that some guys carried the M-76 sub-machine gun but had not seen one while serving my 2 years.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_215_3</DOCNO>
            	<TEXT>I carried an M-79 along with my 40lb medical bags.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_215_4</DOCNO>
            	<TEXT>The M-79 was a grenade launcher which shot 40cal rounds.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_215_5</DOCNO>
            	<TEXT>Let's have a great week coming up!!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_216_0</DOCNO>
            	<TEXT>A great story of an even greater man.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_216_1</DOCNO>
            	<TEXT>One of my good friends was an FO while in Vietnam.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_216_2</DOCNO>
            	<TEXT>We see each other, among many others of which we served, at our annual reunion of the 4th ID Association.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_216_3</DOCNO>
            	<TEXT>This upcoming year we will meet at Fort Carson Colorado.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_216_4</DOCNO>
            	<TEXT>Each years reunion has less and less attendees... We no longer have any WW2 members.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_216_5</DOCNO>
            	<TEXT>While at the reunions I feel so blessed to be in the presence of so many of my heroes........</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_217_0</DOCNO>
            	<TEXT>For the past few years I have been preparing an outline, although slower than my daughters want, to put my stories to print.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_217_1</DOCNO>
            	<TEXT>I need to complete it as none of us know when the clock runs down and the buzzer sounds.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_218_0</DOCNO>
            	<TEXT>This mornings News Release</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_218_1</DOCNO>
            	<TEXT># News Release # Sorrento Therapeutics Announces FDA Clearance of Its IND Application of Next Generation oHSV Oncolytic Virus STI-1386 for Patients With Relapsed and Refractory Solid Tumors December 20, 2021 at 9:00 AM EST[Download PDF](https://investors.sorrentotherapeutics.com/node/12906/pdf) SAN DIEGO, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the U.S. Food and Drug Administration (FDA) has granted clearance to proceed with a Phase 1b clinical trial using STI-1386, Seprehvec, entitled Dose Escalation Study of the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Patients with Relapsed or Refractory Solid Tumors.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_218_2</DOCNO>
            	<TEXT>STI-1386, or Seprehvec, is a 2nd generation oncolytic herpes simplex virus type 1 (oHSV) developed following the acquisition of Virttu Biologics by Sorrento in 2017 and produced in Sorrentos GMP virus therapeutics manufacturing facility.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_218_3</DOCNO>
            	<TEXT>The Seprehvec backbone is deleted of both RL1 gene copies, eliminating expression of the neurovirulence factor ICP34.5 and restricting virus proliferation to cells which are rapidly dividing, i.e., tumor cells.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_218_4</DOCNO>
            	<TEXT>Seprehvec additionally expresses transgenes encoding an anti-PD-1 scFv-Fc isolated from the Sorrento G-MAB antibody library, a TGF beta receptor 2 decoy, and interleukin-12.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_218_5</DOCNO>
            	<TEXT>These transgene-encoded proteins secreted by Seprehvec-infected tumor cells are designed to act in a coordinated fashion to enhance immune-mediated tumor destruction by i) inhibiting the PD-1/PDL-1 immune checkpoint pathway, ii) diminishing the immunosuppressive effects of TGF beta in the tumor microenvironment, and iii) providing a localized IL-12 signal to activate and attract T cells and NK cells to the tumor.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_218_6</DOCNO>
            	<TEXT>Seprehvec allows for locoregional immune stimulation at the tumor site while potentially minimizing the undesired effects that may accompany systemic immune stimulation.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_218_7</DOCNO>
            	<TEXT>Our initial focus is to develop Seprehvec for treatment of sarcomas, pancreatic carcinomas, and hepatic metastases, with expansion to additional solid tumor indications in the future, said Mike Royal, MD, JD, MBA, Chief Medical Officer of Sorrento.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_218_8</DOCNO>
            	<TEXT>Robert Allen, PhD, Senior Vice President of Antiviral and Oncolytic Immunotherapy Development, commented, Seprehvec provides a unique means of simultaneously bringing multiple tumor-killing and tumor-suppressing elements to bear on solid tumors, which are notoriously hard to eradicate.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_218_9</DOCNO>
            	<TEXT>Using this same approach, we are currently progressing additional oHSV candidates that mediate recruitment and activation of anti-tumor responses from specific subsets of immune cells.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_218_10</DOCNO>
            	<TEXT>The virologists, cancer immunologists, and manufacturing scientists at Sorrento continue to leverage the breadth and quality of the G-MAB library, delivering best-in-class next-generation oHSVs, antibodies, and cellular immunotherapies to patients.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_219_0</DOCNO>
            	<TEXT>I was surprised it was not posted when I opened my laptop.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2092_219_1</DOCNO>
            	<TEXT>I had no idea it was just released...</TEXT>
        </DOC>
